[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 940
1. Vieira Santos A, Vilela P, Mateus L, Saraiva PF, Goulão A: [Central nervous system abnormalities namely secondary brain tumors]. Acta Med Port; 2006 Nov-Dec;19(6):451-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central nervous system abnormalities namely secondary brain tumors].
  • [Transliterated title] Tumor do sistema nervoso central secundário a radioterapia e quimioterapia.
  • The authors speculate about the possibility that this tumor may have been radiation and/or chemotherapy induced.
  • Improvement in neuroimaging techniques, in particular magnetic resonance imaging, has helped characterize Central Nervous System abnormalities, namely secondary brain tumours.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioblastoma / diagnosis. Neoplasms, Second Primary / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17583602.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


2. Coronel F D, Gallardo V C, Gamargo G C: [Primary central nervous system lymphoma in an immunocompetent patient: report of a case]. Rev Med Chil; 2008 Apr;136(4):491-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary central nervous system lymphoma in an immunocompetent patient: report of a case].
  • [Transliterated title] Linfoma primario del sistema nervioso central en una paciente inmunocompetente: Caso clínico.
  • Primary central nervous system lymphoma (PCNSL) is a rare tumor.
  • The patient was treated with chemotherapy and whole brain radiotherapy, achieving complete remission of the tumor.
  • [MeSH-major] Brain Neoplasms / diagnosis. Immunocompetence. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / therapeutic use. Biopsy. Female. Humans. Magnetic Resonance Imaging. Methotrexate / therapeutic use. Prognosis. Stem Cells / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769792.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


3. Jiang L, Marlow LA, Cooper SJ, Roemeling CV, Menke DM, Copland JA, Tun HW: Selective central nervous system tropism of primary central nervous system lymphoma. Int J Clin Exp Pathol; 2010;3(8):763-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective central nervous system tropism of primary central nervous system lymphoma.
  • Primary Central nervous system lymphoma (PCNSL) is most frequently a diffuse large B cell lymphoma (DLBCL), which is confined to the Central nervous system (CNS).
  • The lymphoma cells were shown to home to the CNS with histologic evaluations of the brain showing multiple large B cells in blood vessels consistent with intravascular large B cell lymphoma (IVL).
  • The findings are consistent with highly selective tropism of PCNSLforthe CNS and its vasculature.
  • [MeSH-major] Brain Neoplasms / pathology. Central Nervous System Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Animals. Biomarkers, Tumor / metabolism. Brain / blood supply. Brain / pathology. Cell Movement. Fatal Outcome. Female. Humans. Lymphocytes / pathology. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Transplantation. Osteopontin / metabolism. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Feb 1;101(3):815-21 [12393412.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1063-9 [12631608.001]
  • [Cites] Brain. 2003 May;126(Pt 5):1058-67 [12690046.001]
  • [Cites] Pathol Int. 2004 Apr;54(4):231-6 [15028023.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Blood. 2006 Jan 1;107(1):190-6 [16150948.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Dec;20(6):1267-85 [17113462.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3200-10 [18184868.001]
  • [Cites] Curr Oncol Rep. 2009 Jan;11(1):73-80 [19080745.001]
  • [Cites] Blood. 2009 Jan 1;113(1):266-7; author reply 267-8 [19122120.001]
  • (PMID = 21151389.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC2993226
  • [Keywords] NOTNLM ; Lymphoma / central nervous system / tropism
  •  go-up   go-down


Advertisement
4. Beltrán MA, Barría C, Contreras MA, Wilson CS, Cruces KS: [Gastrointestinal stromal tumor (GIST) in a patient with neurofibromatosis type 1. Report of one case]. Rev Med Chil; 2009 Sep;137(9):1197-200
Genetic Alliance. consumer health - Neurofibromatosis type 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal stromal tumor (GIST) in a patient with neurofibromatosis type 1. Report of one case].
  • [Transliterated title] Tumor del estroma gastrointestinal (GIST) en una paciente con neurofibromatosis tipo 1.
  • Neurofibromatosis Type 1 (NF1) is an autosomic dominant condition affecting the central nervous system and presenting a disposition towards development of gastrointestinal stromal tumors (GIST).
  • The pathological study showed a partially necrotic solid-cystic tumor with 1 to 2 mitoses per 50-high-power fields.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Neurofibromatosis 1 / complications
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20011961.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


5. Guinto-Balanzar G, Félix-Espinoza I, Ponce-de-León Sde A, Aréchiga-Ramos NC, Arteaga-Larios V, Kovacs K: [Primary central nervous system lymphoma in immunocompetent patients]. Gac Med Mex; 2005 Nov-Dec;141(6):469-76
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary central nervous system lymphoma in immunocompetent patients].
  • [Transliterated title] Linfoma primario del sistema nervioso central en pacientes inmunocompetentes.
  • Primary central nervous system lymphoma has been traditionally described in patients with immunodeficiency syndromes; however, there is an increasing number of immunocompetent patients with this type of tumor that have been reported recently.
  • The majority of tumors were histologically classified as diffuse large cells and all of them showed a positive reaction to B-cells antigens on immunohistochemistry.
  • [MeSH-major] Brain Neoplasms. Lymphoma, B-Cell
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunocompetence. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381500.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


6. Combs SE, Thilmann C, Debus J, Schulz-Ertner D: Precision radiotherapy for hemangiopericytomas of the central nervous system. Cancer; 2005 Dec 1;104(11):2457-65
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precision radiotherapy for hemangiopericytomas of the central nervous system.
  • The present analysis evaluates the role of precision RT in the management of HAP of the central nervous system (CNS) and represents one of the largest series of HAP treated with RT that can be found in the literature.
  • METHODS: Of 37 consecutive patients with histologically confirmed HAP who were treated at the institution between 1984 and 2004, the majority, 25 tumors, was localized within the skull base (n = 25) and 4 tumors were localized at the spine.
  • CONCLUSION: High-precision RT is an effective and safe treatment modality for patients with HAP of the CNS and the spine and achieves highly acceptable tumor control, while sparing normal tissue.
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Hemangiopericytoma / radiotherapy. Radiotherapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Follow-Up Studies. Humans. Middle Aged. Retrospective Studies. Stereotaxic Techniques. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222690.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Julve Parreño A, Ponce Pérez E, Dosdá Muñoz R, Soler Martínez J: [Localized fibrous tumor of the pleura: radiological findings]. Radiologia; 2007 Sep-Oct;49(5):339-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Localized fibrous tumor of the pleura: radiological findings].
  • [Transliterated title] Tumor fibroso localizado de la pleura: hallazgos radiológicos.
  • Localized fibrous tumors of the pleura are rare tumors that represent less than 5% of the pleural tumors, although they have also been described in extrathoracic locations such as the abdomen, head and neck or central nervous system.
  • These are slow growing tumors.
  • [MeSH-major] Solitary Fibrous Tumor, Pleural / radiography
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910870.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. Fischer L, Korfel A, Pfeiffer S, Kiewe P, Volk HD, Cakiroglu H, Widmann T, Thiel E: CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res; 2009 Oct 1;15(19):5968-73
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCL13 and CXCL12 in central nervous system lymphoma patients.
  • PURPOSE: Homing of malignant lymphocytes to the central nervous system (CNS) may play a role in the pathogenesis of CNS lymphoma.
  • In this study, we evaluated the chemokines CXCL12 and CXCL13 in the cerebrospinal fluid (CSF) and serum of patients with CNS lymphoma.
  • EXPERIMENTAL DESIGN: Samples from 30 patients with CNS lymphoma (23 with primary and 7 with secondary CNS lymphoma; all B-cell lymphoma) and 40 controls (10 patients with other CNS malignancies and 30 without a malignant CNS disease) were examined.
  • RESULTS: CNS lymphoma patients and controls did not differ in CXCL12 serum and CSF levels.
  • CXCL13 CSF levels, however, were significantly higher in CNS lymphoma patients as compared with controls (P < 0.0001).
  • In CNS lymphoma, CXCL13 concentration in CSF correlated with the degree of blood-brain barrier disruption (R = 0.66; P = 0.003).
  • Elevated CSF levels of CXCL12 and CXCL13 measured in seven CNS lymphoma patients during therapy decreased in five patients who responded to chemotherapy and increased in two with lymphoma progression.
  • CONCLUSIONS: Our results suggest a production of CXCL13 within the CNS of CNS lymphoma patients, which decreases with response to therapy.
  • [MeSH-major] Central Nervous System Neoplasms / blood. Central Nervous System Neoplasms / cerebrospinal fluid. Chemokine CXCL12. Chemokine CXCL13. Lymphoma / blood. Lymphoma / cerebrospinal fluid
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Biomarkers, Tumor / cerebrospinal fluid. Case-Control Studies. Disease Progression. Female. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773382.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / Chemokine CXCL12; 0 / Chemokine CXCL13; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


9. Eap C, Litré CF, Noudel R, Theret E, Duntze J, Collin P, Rousseaux P: [Primitive malignant rhabdoid tumor of the central nervous system in an adolescent. A case study]. Neurochirurgie; 2010 Oct;56(5):404-7
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primitive malignant rhabdoid tumor of the central nervous system in an adolescent. A case study].
  • [Transliterated title] Tumeur rhabdoïde du système nerveux central chez une adolescente de 16ans : à propos d'un cas.
  • Primitive malignant rhabdoid tumors of the central nervous system are rare and have a poor prognosis.
  • Adult and adolescent cases are exceptional.
  • We report the case of a 16-year-old girl who presented an intratumoral hemorrhage in a rhabdoid tumor.
  • We discuss the different therapeutic options for this patient and review the literature on this kind of tumor.
  • [MeSH-major] Brain Neoplasms. Rhabdoid Tumor

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Masson SAS.
  • (PMID = 20594960.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Crawford JR, Santi MR, Cornelison R, Sallinen SL, Haapasalo H, MacDonald TJ: Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors. J Neurooncol; 2009 Oct;95(1):49-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors.
  • The purpose is to determine the incidence of active and latent human herpesvirus-6 (HHV-6) infection in a large cohort of adult primary and recurrent CNS tumors.
  • We screened a tissue microarray (TMA) containing more than 200 adult primary and recurrent CNS tumors with known clinical information for the presence of HHV-6 DNA by in situ hybridization (ISH) and protein by immunohistochemistry (IHC).
  • One hundred six of 224 (47%) CNS tumors were positive for HHV-6 U57 Major Capsid Protein (MCP) gene by ISH compared to 0/25 non tumor control brain (P = 0.001).
  • Fourteen of 30 (47%) tumors were HHV-6 MCP positive by nested PCR compared to 0/25 non-tumor brain controls (P = 0.001), revealing HHV-6 Variant A in 6 of 14 samples.
  • HHV-6A/B early (p41) and late (gp116/64/54) antigens were detected by IHC in 66 of 277 (24%) (P = 0.003) and 84 of 282 (35%) (P = 0.002) tumors, respectively, suggesting active infection.
  • Glial tumors were 3 times more positive by IHC compared to non glial tumors for both HHV-6 gp116/64/54 (P = 0.0002) and HHV-6 p41 (P = 0.004).
  • HHV-6 early and late antigens are detected in adult primary and recurrent CNS tumors more frequently in glial tumors.
  • We hypothesize that the glial-tropic features of HHV-6 may play an important modifying role in tumor biology that warrants further investigation.
  • [MeSH-major] Antigens, Viral. Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / virology. Glioma / genetics. Glioma / virology. Herpesvirus 6, Human / isolation & purification
  • [MeSH-minor] Adult. Antigens, CD / metabolism. CD48 Antigen. Capsid Proteins / genetics. Capsid Proteins / metabolism. Humans. Survival Analysis. Viral Envelope Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424665.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K12NS052159-01A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Viral; 0 / CD48 Antigen; 0 / Capsid Proteins; 0 / Viral Envelope Proteins
  •  go-up   go-down


11. Saint-Blancard P, Harket A, Tine I, Daumas-Duport C, de Soultrait FR: [A rare lesion of the central nervous system: inflammatory pseudotumor]. Neurochirurgie; 2008 Feb;54(1):37-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A rare lesion of the central nervous system: inflammatory pseudotumor].
  • [Transliterated title] Une lésion rare du système nerveux central: la pseudotumeur inflammatoire.
  • Inflammatory pseudotumor is an uncommon tumor, initially described in the lung, but which can involve various organs.
  • We report the case of a 19-year-old-man with an inflammatory pseudotumor localized in the central nervous system, revealed by epilepsy.
  • Relatively ubiquitous, this tumor is seldom described in the central nervous system.
  • [MeSH-major] Central Nervous System Diseases / pathology. Granuloma, Plasma Cell / pathology
  • [MeSH-minor] Adult. Epilepsy / etiology. Fibrosis. Frontal Lobe / pathology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18280522.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Becker H: [Intracerebral hemorrhage misjudged as tumor]. Clin Neuroradiol; 2010 Aug;20(3):161-4
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracerebral hemorrhage misjudged as tumor].
  • [Transliterated title] Intrazerebrale Blutung als Tumor verkannt.
  • The patient was informed that she had a tumor.
  • [MeSH-major] Brain Neoplasms / radiography. Cerebral Hemorrhage / radiography. Diagnostic Errors / prevention & control. Hemangioma, Cavernous, Central Nervous System / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625692.001).
  • [ISSN] 1869-1447
  • [Journal-full-title] Clinical neuroradiology
  • [ISO-abbreviation] Clin Neuroradiol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Calugaru V, Taillibert S, Lang P, Simon JM, Delattre JY, Mazeron JJ: [Neoadjuvant chemotherapy followed by radiotherapy adapted to the tumor response in the primary germinoma of the central nervous system: experience of the Pitié-Salpêtrière Hospital and review of literature]. Cancer Radiother; 2007 May;11(3):122-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant chemotherapy followed by radiotherapy adapted to the tumor response in the primary germinoma of the central nervous system: experience of the Pitié-Salpêtrière Hospital and review of literature].
  • [Transliterated title] Chimiothérapie néoadjuvante suivie d'une radiothérapie adaptée à la réponse tumorale dans les tumeurs germinales séminomateuses du système nerveux central: expérience de l'hôpital de la Pitié-Salpêtrière et revue de la littérature.
  • PURPOSE: Retrospective analysis of ten cases of germinoma of the central nervous system treated in Pitié-Salpêtrière Hospital, Paris.
  • PATIENTS AND METHODS: Ten male patients were treated from 1997 to 2005 for histologically verified primary seminoma of the central nervous system.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Germinoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Neoadjuvant Therapy. Radiotherapy Dosage. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies

  • Genetic Alliance. consumer health - Germinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459755.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 44
  •  go-up   go-down


14. Chtourou I, Krichen Makni S, Bahri I, Ellouze S, Khabir A, Ben Ali H, Daoud J, Boudawara TS: [Rhabdoid tumours of the central nervous system: five case studies]. Cancer Radiother; 2006 May;10(3):112-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rhabdoid tumours of the central nervous system: five case studies].
  • [Transliterated title] Les tumeurs rhabdoïdes du système nerveux central: à propos de cinq observations.
  • PURPOSE: The rhabdoid cerebral tumors were first identified by Briner et al. in 1985.
  • Such tumors are equally characterized by a critically and speedly mortal development.
  • The aim of the present study was to discuss the various anatomicoclinical and therapeutic aspects of these rare tumors.
  • Radiography through magnetic resonance revealed a heterogeneous tumor process localized respectively on the spine (one case), the insula (one case), the temporofrontal lobes (two cases) and the medulla (one case).
  • Histological examination of the tumors also showed a proliferation of giant cells with a hyaline-based cytoplasmic inclusion.
  • A recurrence of rhabdoid tumors occurred in two cases.
  • CONCLUSION: The cerebral rhabdoid malignant tumor constitutes one of the most aggressive and life-threatening intracranial tumors.
  • The optimal management of such tumors remains unknown.
  • [MeSH-major] Central Nervous System Neoplasms. Rhabdoid Tumor
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Infant. Male. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16616869.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


15. Fitzgerald DP, Bradford D, Cooper HM: Neogenin is expressed on neurogenic and gliogenic progenitors in the embryonic and adult central nervous system. Gene Expr Patterns; 2007 Aug;7(7):784-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neogenin is expressed on neurogenic and gliogenic progenitors in the embryonic and adult central nervous system.
  • Here we have undertaken a detailed analysis of Neogenin expression in the embryonic mouse central nervous system at key developmental time points.
  • Adult neural stem cells found in the subventricular zone of the lateral ventricle of the rodent forebrain are direct descendants of the embryonic striatal radial glial population.
  • Here we show that Neogenin expression is maintained in the neural stem cell population of the adult mouse forebrain.
  • In summary, this study demonstrates that Neogenin expression is a hallmark of many neural precursor populations (neurogenic and gliogenic) in both the embryonic and adult mammalian central nervous system.
  • [MeSH-major] Central Nervous System / embryology. Gene Expression Regulation, Developmental. Membrane Proteins / physiology. Neuroglia / metabolism. Neurons / metabolism. Prosencephalon / embryology
  • [MeSH-minor] Animals. Brain / metabolism. Immunohistochemistry. Mice. Mice, Inbred C57BL. Nerve Growth Factors / metabolism. Stem Cells / cytology. Telencephalon / metabolism. Time Factors. Tumor Suppressor Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17604699.001).
  • [ISSN] 1567-133X
  • [Journal-full-title] Gene expression patterns : GEP
  • [ISO-abbreviation] Gene Expr. Patterns
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Nerve Growth Factors; 0 / Tumor Suppressor Proteins; 0 / neogenin; 158651-98-0 / netrin-1
  •  go-up   go-down


16. Cheng YC, Lirng JF, Chang FC, Guo WY, Teng MM, Chang CY, Wong TT, Ho DM: Neuroradiological findings in atypical teratoid/rhabdoid tumor of the central nervous system. Acta Radiol; 2005 Feb;46(1):89-96
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroradiological findings in atypical teratoid/rhabdoid tumor of the central nervous system.
  • PURPOSE: To evaluate the computed tomography (CT) and magnetic resonance imaging (MRI) findings of atypical teratoid tumor/rhabdoid tumor (AT/RT) of the central nervous system (CNS).
  • MATERIAL AND METHODS: Twenty cases of CNS AT/RT have been found over the past 23 years in our hospital; these involving 11 boys and 9 girls whose mean age at diagnosis was 5.5 years.
  • However, AT/RT should still remain in the differential diagnosis of brain tumors in young children, especially those located in the cerebellar hemisphere and with eccentric cysts.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / radiography. Rhabdoid Tumor / pathology. Rhabdoid Tumor / radiography. Teratoma / pathology. Teratoma / radiography
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Prognosis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841745.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


17. Wu W, Shi JX, Cheng HL, Wang HD, Hang CH, Shi QL, Yin HX: Hemangiopericytomas in the central nervous system. J Clin Neurosci; 2009 Apr;16(4):519-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangiopericytomas in the central nervous system.
  • Hemangiopericytomas, which are more aggressive than meningiomas, are rare in the central nervous system (CNS).
  • We analyzed the clinical, radiological and histological features and treatment of 26 patients with hemangiopericytomas in the CNS.
  • Most tumors were located in the parasagittal and falx regions.
  • The tumors were dense or mixed as assessed by CT scans, and most were homogeneously enhanced.
  • Most tumors were isointense on T1-weighted MRI, and high or mixed intensity on T2-weighted MRI; they were homogeneously or heterogeneously enhanced.
  • Histological examination indicated numerous small vascular spaces in the tumor.
  • All tumors were immunohistochemically positive for vimentin.
  • Surgical removal and post-operative radiotherapy are thus critical for the treatment of this tumor.
  • [MeSH-major] Central Nervous System Neoplasms. Hemangiopericytoma
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neurosurgical Procedures / methods. Radiotherapy. Retrospective Studies. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246200.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


18. Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH: Central nervous system tumors. Mayo Clin Proc; 2007 Oct;82(10):1271-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system tumors.
  • Central nervous system tumors are relatively common in the United States, with more than 40,000 cases annually.
  • Although more than half of these tumors are benign, they can cause substantial morbidity.
  • Malignant primary brain tumors are the leading cause of death from solid tumors in children and the third leading cause of death from cancer in adolescents and adults aged 15 to 34 years.
  • Whereas magnetic resonance imaging helps define the anatomic extent of tumor, biopsy is often required to confirm the diagnosis.
  • Benign tumors are usually curable with surgical resection or radiation therapy including stereotactic radiation; however, most patients with malignant brain tumors benefit from chemotherapy either at the time of initial diagnosis or at tumor recurrence.
  • Metastases to the brain remain a frequent and morbid complication of solid tumors but are frequently controlled with surgery or radiation therapy.
  • Unfortunately, the mortality rate from malignant brain tumors remains high, despite initial disease control.
  • This article provides an overview of current diagnostic and treatment approaches for patients with primary and metastatic brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Glioma / diagnosis. Glioma / therapy. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908533.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


19. Wang Z, Fan QH, Yu MN, Zhang WM: [Clinicopathologic and immunohistochemical study of atypical teratoid/rhabdoid tumor of central nervous system]. Zhonghua Bing Li Xue Za Zhi; 2006 Aug;35(8):458-61
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic and immunohistochemical study of atypical teratoid/rhabdoid tumor of central nervous system].
  • OBJECTIVE: To study the clinicopathologic features and differential diagnosis of atypical teratoid/rhabdoid tumor (AT/RT) occurring in the central nervous system.
  • The tumor cells were positive for vimentin, CD99, epithelial membrane antigen, cytokeratin, glial fibrillary acidic protein, S-100 protein, neurofilament, desmin and smooth muscle actin.
  • CONCLUSIONS: AT/RT is a highly malignant tumor occurring in the central nervous system.
  • The tumor is characterized by a heterogeneous histologic and immunohistochemical phenotype.
  • It needs to be distinguished from a number of central nervous system tumors, including medulloblastoma, primitive neuroectodermal tumor, germ cell neoplasm and rhabdoid meningioma.
  • [MeSH-major] Brain Neoplasms / pathology. Rhabdoid Tumor / pathology. Teratoma / pathology
  • [MeSH-minor] Actins / analysis. Adult. Antigens, CD / analysis. Cell Adhesion Molecules / analysis. Child, Preschool. Desmin / analysis. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Keratins / analysis. Male. Mucin-1 / analysis. Muscle, Smooth / chemistry. Neurofilament Proteins / analysis. S100 Proteins / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17069697.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Desmin; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Neurofilament Proteins; 0 / S100 Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


20. Gélinas DS, Lambermon MH, McLaurin J: Ciglitazone increases basal cytokine expression in the central nervous system of adult rats. Brain Res; 2005 Feb 9;1034(1-2):139-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ciglitazone increases basal cytokine expression in the central nervous system of adult rats.
  • In the present study, we sought to investigate the effects of oral administration of ciglitazone on basal inflammatory cytokine expression in healthy adult rats.
  • Our results show that despite anti-inflammatory effects described for ciglitazone in "primed" models, ciglitazone can positively modulate basal inflammatory mediators within the central nervous system (CNS) of healthy adult rodents.
  • [MeSH-major] Central Nervous System / drug effects. Cytokines / metabolism. Hypoglycemic Agents / pharmacology. Thiazolidinediones / pharmacology. Up-Regulation / drug effects
  • [MeSH-minor] Animals. Female. Infusion Pumps. Interleukin-1 / genetics. Interleukin-1 / metabolism. Interleukin-4 / metabolism. PPAR gamma / genetics. RNA, Messenger / drug effects. RNA, Messenger / metabolism. Rats. Rats, Inbred F344. Spleen / drug effects. Spleen / immunology. Spleen / metabolism. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15713265.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Hypoglycemic Agents; 0 / Interleukin-1; 0 / PPAR gamma; 0 / RNA, Messenger; 0 / Thiazolidinediones; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4; 74772-77-3 / ciglitazone
  •  go-up   go-down


21. Swain RS, Tihan T, Horvai AE, Di Vizio D, Loda M, Burger PC, Scheithauer BW, Kim GE: Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor. Hum Pathol; 2008 Mar;39(3):410-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor.
  • Inflammatory myofibroblastic tumor (IMT) is a distinctive spindle cell lesion and occurs primarily in soft tissue.
  • IMT in the central nervous system (CNS) is rare, its characteristics are poorly defined, and its relation to similar tumors at other sites is unclear.
  • To better characterize IMT within the CNS, we studied clinicopathologic features of 6 IMTs and compared them with 18 nonneoplastic lesions originally classified as IP.
  • All tumors were composed of neoplastic spindle cells and a variable amount of inflammatory infiltrate.
  • We suggest that IMT in the CNS is distinct from the nonneoplastic IP, and distinguishing IMT from nonneoplastic lesions should enable better decisions for patient management.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Granuloma, Plasma Cell / classification. Granuloma, Plasma Cell / pathology. Myofibroma / classification. Myofibroma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Male. Middle Aged

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261625.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gyure KA: Newly defined central nervous system neoplasms. Am J Clin Pathol; 2005 Jun;123 Suppl:S3-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Newly defined central nervous system neoplasms.
  • In recent years, numerous new entities or variants of recognized central nervous system tumors have been described in the literature, and the morphologic spectrum of these neoplasms is delineated incompletely.
  • The clinicopathologic features and differential diagnosis of 4 new entities, including the chordoid glioma of the third ventricle, cerebellar liponeurocytoma, atypical teratoid/rhabdoid tumor, and papillary glioneuronal tumor, are discussed in this review.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / diagnosis
  • [MeSH-minor] Adult. Cerebellar Neoplasms / classification. Cerebellar Neoplasms / diagnosis. Child. Chordoma / classification. Chordoma / diagnosis. Diagnosis, Differential. Female. Ganglioglioma / classification. Ganglioglioma / diagnosis. Glioma / diagnosis. Glioma / pathology. Humans. Hypothalamic Neoplasms / classification. Hypothalamic Neoplasms / diagnosis. Male. Medulloblastoma / classification. Medulloblastoma / diagnosis. Prognosis. Rhabdoid Tumor / classification. Rhabdoid Tumor / diagnosis. Teratoma / classification. Teratoma / diagnosis. Third Ventricle / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100866.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 81
  •  go-up   go-down


23. Umredkar A, Bal A, Vashista RK: Atypical teratoid/rhabdoid tumour of the central nervous system in adult: case report. Br J Neurosurg; 2010 Dec;24(6):699-704

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumour of the central nervous system in adult: case report.
  • Atypical teratoid/rhabdoid tumours (AT/RT) are aggressive neoplasms of the central nervous system occurring mainly in the paediatric population.
  • The neoplasm was localised in the left frontal region and was totally excised.
  • This unusual presentation underlines the necessity of considering this devastating neoplasm in the differential diagnosis of malignant brain tumours of adults.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Rhabdoid Tumor / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21070155.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Erickson ML, Johnson R, Bannykh SI, de Lotbiniere A, Kim JH: Malignant rhabdoid tumor in a pregnant adult female: literature review of central nervous system rhabdoid tumors. J Neurooncol; 2005 Sep;74(3):311-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant rhabdoid tumor in a pregnant adult female: literature review of central nervous system rhabdoid tumors.
  • Rhabdoid tumors of the central nervous system are uncommon, aggressive childhood malignancies.
  • The 13 described adult cases comprise both primary CNS tumors and malignant transformation of previously existing gliomas, meningiomas, and astrocytomas.
  • Central nervous system rhabdoid lesions of adults have been diagnosed as primary malignant rhabdoid tumors, atypical teratoid/rhabdoid tumors, and more recently, rhabdoid glioblastomas.
  • Pathologic evaluation revealed histology, electron microscopy and immunohistochemistry consistent with the diagnosis of malignant rhabdoid tumor.
  • FISH studies were negative for the INI-1 genetic mutations and chromosome 22q deletion associated with childhood atypical rhabdoid/rhabdoid tumor in 75% of cases.
  • We briefly describe the characteristics and current understanding of rhabdoid tumors, and review the literature comparing the 12 other cases of central nervous system rhabdoid tumors in adults.
  • Furthermore, we consider and discuss the implications of this case being the second presentation of MRT during pregnancy in only six adult female patients.
  • [MeSH-major] Brain Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Microscopy, Electron, Transmission. Pregnancy


25. Jansen AM, Nässel DR, Madsen KL, Jung AG, Gether U, Kjaerulff O: PICK1 expression in the Drosophila central nervous system primarily occurs in the neuroendocrine system. J Comp Neurol; 2009 Nov 20;517(3):313-32
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PICK1 expression in the Drosophila central nervous system primarily occurs in the neuroendocrine system.
  • To study PICK1 in an intact system, we characterized PICK1 expression immunohistochemically in the adult and larval Drosophila central nervous system.
  • In contrast, we detected robust PICK1 immunolabeling of peptidergic neurons in the neuroendocrine system, which express the transcription factor DIMM and the amidating enzyme peptidylglycine-alpha-hydroxylating monooxygenase (PHM).
  • We conclude that PICK1 may serve an important role in the neuroendocrine system both in insects and vertebrates.
  • [MeSH-minor] Animals. Animals, Genetically Modified. Brain / growth & development. Brain / metabolism. Cell Line, Tumor. Dopamine / metabolism. Glutamic Acid / metabolism. Immunohistochemistry. Larva / growth & development. Larva / metabolism. Mutation. Neurosecretory Systems / growth & development. Neurosecretory Systems / metabolism. Peripheral Nervous System / growth & development. Peripheral Nervous System / metabolism. Rats. Spinal Cord / growth & development. Spinal Cord / metabolism. gamma-Aminobutyric Acid / metabolism

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • FlyBase. FlyBase .
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DOPAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19757495.001).
  • [ISSN] 1096-9861
  • [Journal-full-title] The Journal of comparative neurology
  • [ISO-abbreviation] J. Comp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Drosophila Proteins; 0 / ILP2 protein, Drosophila; 0 / PICK1 protein, Drosophila; 3KX376GY7L / Glutamic Acid; 56-12-2 / gamma-Aminobutyric Acid; VTD58H1Z2X / Dopamine
  •  go-up   go-down


26. Sawada T, Kato Y, Kobayashi M: Expression of aquaporine-4 in central nervous system tumors. Brain Tumor Pathol; 2007;24(2):81-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of aquaporine-4 in central nervous system tumors.
  • Cerebral edema is associated with common brain tumors.
  • To elucidate the characterization of the expression of AQP4 and the relationship of the expression of VEGF, we investigated the expression of AQP4 in tumors of the central nervous system immunohistochemically.
  • Brain tumors and nontumorous cerebral tissue for control were evaluated by immunohistochemical staining using anti-AQP4, VEGF, CD34, and MIB-1.
  • In tumor cells, only glial tumor cells showed a positive reaction for AQP4.
  • Although endothelial cells were negative and/or weakly positive for AQP4, the positive relationship suggested the expression of VEGF in endothelial cells in neovasculature and that of AQP 4 in tumor cells.
  • APQ4 expression increased in human astrocytic tumors and edematous cerebral tissue.
  • Upregulation of APQ4 by tumor cells and reactive astroglia were major factors of cerebral edema.
  • [MeSH-major] Aquaporin 4 / biosynthesis. Brain Neoplasms / metabolism. Brain Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Astrocytes / metabolism. Brain Edema / etiology. Brain Edema / metabolism. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. Receptors, Vascular Endothelial Growth Factor / biosynthesis. Up-Regulation. Vascular Endothelial Growth Factor A / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095136.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Aquaporin 4; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


27. Gläsker S, Van Velthoven V: Risk of hemorrhage in hemangioblastomas of the central nervous system. Neurosurgery; 2005 Jul;57(1):71-6; discussion 71-6
MedlinePlus Health Information. consumer health - Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of hemorrhage in hemangioblastomas of the central nervous system.
  • OBJECTIVE: Hemangioblastomas are benign vascular tumors of the central nervous system.
  • Several cases of spontaneous hemorrhage within these tumors have been reported.
  • However, the risk of hemorrhage in these tumors remains unknown.
  • METHODS: To clarify the incidence of hemorrhage in hemangioblastomas, we reviewed our large clinical database of 277 patients with central nervous system hemangioblastomas for the incidence of spontaneous or perioperative hemorrhage.
  • Clinical characteristics such as tumor size, tumor location, von Hippel-Lindau disease status, and clinical symptoms before hemorrhage were correlated with hemorrhage risk.
  • The average diameter of tumors that bled was 3 cm in our series and 2.3 cm in the literature review, whereas the average diameter of hemangioblastomas in major series ranges from 0.8 to 1.1 cm.
  • An important indicator for the probability of hemorrhage is tumor size, as spontaneous or postoperative hemorrhage occurred exclusively in extraordinarily large tumors.
  • Hemangioblastomas smaller than 1.5 cm (the vast majority of these tumors) harbor virtually no risk of spontaneous hemorrhage.
  • [MeSH-major] Central Nervous System Neoplasms / physiopathology. Hemangioblastoma / physiopathology. Hemorrhage / etiology. Risk
  • [MeSH-minor] Adult. Aged. Clinical Trials as Topic. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neurosurgery / methods. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15987542.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


28. Kamnasaran D, Guha A: Expression of GATA6 in the human and mouse central nervous system. Brain Res Dev Brain Res; 2005 Nov 7;160(1):90-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of GATA6 in the human and mouse central nervous system.
  • The expression profile of GATA6 has been poorly defined in the central nervous system (CNS).
  • In this report, we identify GATA6 expression in the normal mouse and human CNS, using Northern blot analyses, immunohistochemistry (IHC), and immunofluorescence (IF).
  • GATA6 is expressed as a 2.2 kb transcript in the adult mouse brain and several regions of the adult human brain.
  • [MeSH-major] Astrocytes / metabolism. Central Nervous System / growth & development. Endothelial Cells / metabolism. GATA6 Transcription Factor / metabolism. Gene Expression Regulation, Developmental / genetics. Neurons / metabolism
  • [MeSH-minor] Aging / genetics. Aging / metabolism. Animals. Animals, Newborn. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Cell Differentiation / genetics. Cell Line. Choroid Plexus / metabolism. Genes, Tumor Suppressor / physiology. Glioma / genetics. Glioma / metabolism. Humans. Immunohistochemistry. Mice. Protein Isoforms / genetics. Protein Isoforms / metabolism. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150495.001).
  • [ISSN] 0165-3806
  • [Journal-full-title] Brain research. Developmental brain research
  • [ISO-abbreviation] Brain Res. Dev. Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / GATA6 Transcription Factor; 0 / GATA6 protein, human; 0 / Protein Isoforms; 0 / RNA, Messenger
  •  go-up   go-down


29. McMillan A: Central nervous system-directed preventative therapy in adults with lymphoma. Br J Haematol; 2005 Oct;131(1):13-21
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system-directed preventative therapy in adults with lymphoma.
  • All adult patients with Burkitt lymphoma or lymphoblastic lymphoma should receive central nervous system (CNS)-directed therapy with both intrathecal and high-dose systemic chemotherapy.
  • There is no evidence to support the routine use of prophylactic CNS-directed therapy in any specific subgroup of adult patients with 'low grade' lymphomas.
  • There are some anatomical sites where involvement by lymphoma is associated with a higher risk of CNS relapse.
  • Multivariate analyses strongly support a raised serum lactate dehydrogenase level and the involvement of more than one extranodal site as the strongest predictors of subsequent CNS relapse.
  • It is not clear how the best balance between the 'sensitivity' and 'specificity' of the choice of patients to receive CNS-directed therapy can be achieved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / prevention & control. Lymphoma / prevention & control
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Burkitt Lymphoma / blood. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / prevention & control. Female. Humans. Injections, Spinal. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control. Prognosis. Recurrence. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173958.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  • [Number-of-references] 47
  •  go-up   go-down


30. Inda MM, Castresana JS: RASSF1A promoter is highly methylated in primitive neuroectodermal tumors of the central nervous system. Neuropathology; 2007 Aug;27(4):341-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RASSF1A promoter is highly methylated in primitive neuroectodermal tumors of the central nervous system.
  • Although cancer is rare in children, primary brain tumors constitute the most frequent location of solid tumors in childhood.
  • Primitive neuroectodermal tumors (PNET) of the central nervous system can be divided into infratentorial PNET or medulloblastoma (MB), and supratentorial (sPNET) tumors.
  • The RASSF1A (Ras Association Domain Family Protein 1) gene, located at 3p21.3, is highly methylated in multiple primary tumor samples, including neuroblastoma.
  • Therefore, the inactivation of the RASSF1A gene seems to be an important step in the tumorigenesis of PNET of the central nervous sytem.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Medulloblastoma / genetics. Neuroectodermal Tumors, Primitive / genetics. Promoter Regions, Genetic. Supratentorial Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. DNA Methylation. Female. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899687.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


31. Zhou J, Wang J, Li N, Zhang X, Zhou H, Zhang R, Ma H, Zhou X: Molecularly genetic analysis of von Hippel-Lindau associated central nervous system hemangioblastoma. Pathol Int; 2010 Jun;60(6):452-8
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecularly genetic analysis of von Hippel-Lindau associated central nervous system hemangioblastoma.
  • Von Hippel-Lindau (VHL) disease is an autosomal dominant inherited cancer predisposition syndrome, characterized by development of a variety of neoplasms in multiple organs.
  • Central nervous system hemangioblastoma (CHB) is the most common manifestation of VHL disease.
  • The germline mutations in the VHL tumor suppressor gene are responsible for the inherited cancer predisposition syndrome.
  • To expand the VHL mutation data and to investigate the tumorigenesis of VHL-associated CNS hemangioblastoma, 24 CHB tissue samples and blood samples of 14 patients from 10 Chinese VHL families were collected and subjected to molecular genetic analysis.
  • In addition, expression of the ZAC1 tumor suppressor gene protein was studied using immunohistochemistry staining in CHB tissues with a specific polyclonal antibody.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Germ-Line Mutation / genetics. Hemangioblastoma / genetics. von Hippel-Lindau Disease / genetics
  • [MeSH-minor] Adolescent. Adult. Cell Cycle Proteins / genetics. Cell Cycle Proteins / metabolism. Child. DNA Mutational Analysis. Family Health. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Nuclear Family. Point Mutation. Transcription Factors / genetics. Transcription Factors / metabolism. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism. Von Hippel-Lindau Tumor Suppressor Protein / genetics. Von Hippel-Lindau Tumor Suppressor Protein / metabolism. Young Adult

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518900.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / PLAGL1 protein, human; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


32. Theeler BJ, Keylock J, Yoest S, Forouhar M: Ewing's sarcoma family tumors mimicking primary central nervous system neoplasms. J Neurol Sci; 2009 Sep 15;284(1-2):186-9
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma family tumors mimicking primary central nervous system neoplasms.
  • Ewing's sarcoma family tumors (ESFTs) and embyronal tumors of the central nervous system are malignant primitive neuroectodermal tumors (PNETs) that can arise in the central nervous system, bones, or soft tissues.
  • When ESFTs involve the central nervous system or nearby structures the diagnosis depends on cytogenetics and immunohistochemistry as these tumors can appear otherwise histologically identical to central PNETs.
  • We present two cases of isolated central nervous system presentations of ESFTs mimicking primary central nervous system neoplasms.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Neuroectodermal Tumors, Primitive / diagnosis. Sarcoma, Ewing / diagnosis. Skull Neoplasms / diagnosis. Spinal Neoplasms / diagnosis. Temporal Bone / pathology. Thoracic Vertebrae
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Calmodulin-Binding Proteins / genetics. Cell Adhesion Molecules / analysis. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Epidural Space. Female. Headache / etiology. Humans. Male. Memory Disorders / etiology. RNA-Binding Proteins / genetics. Spinal Cord Compression / etiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394051.001).
  • [ISSN] 1878-5883
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Calmodulin-Binding Proteins; 0 / Cell Adhesion Molecules; 0 / EWSR1 protein, human; 0 / RNA-Binding Proteins
  •  go-up   go-down


33. Uematsu Y, Fukai J, Okita R, Owai Y, Fujita K, Tanaka Y, Itakura T: Intra-axial pseudotumors in the central nervous system: clinicopathological analysis. Brain Tumor Pathol; 2010 Oct;27(2):71-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-axial pseudotumors in the central nervous system: clinicopathological analysis.
  • Intra-axial pseudotumors in the central nervous system often mimic malignant brain tumors and cause difficulty in diagnosis and treatment.
  • MRI demonstrated perifocal edema and ring-like or solid enhancement, mimicking the malignant tumors.
  • These results suggested that intra-axial pseudotumors in the central nervous system contain various kinds of pathology, and detailed clinicopathological analysis is important from the point of view of differential diagnosis.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Pseudotumor Cerebri / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Abscess / pathology. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Cell Count. Cerebral Angiography. Coloring Agents. Demyelinating Diseases / pathology. Female. Gliosis / pathology. Histiocytosis, Non-Langerhans-Cell / pathology. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Tissue Fixation. Tomography, Emission-Computed, Single-Photon. Vasculitis, Central Nervous System / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046308.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


34. Jeon YK, Chang KH, Suh YL, Jung HW, Park SH: Inflammatory myofibroblastic tumor of the central nervous system: clinicopathologic analysis of 10 cases. J Neuropathol Exp Neurol; 2005 Mar;64(3):254-9
Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the central nervous system: clinicopathologic analysis of 10 cases.
  • To verify the pathologic features, anaplastic lymphoma kinase (ALK) expression and biologic behavior of inflammatory myofibroblastic tumors (IMTs) of the central nervous system (CNS), we analyzed 10 cases of IMTs-CNS (8 cranial, 1 spinal, and 1 orbital).
  • Our series of IMTs of the CNS showed a male predominance (male:female = 6:4) and a wide age range (10-60 years; mean age, 46.7 years).
  • ALK expression was not found in our IMTs of the CNS.
  • Pathologically, IMT-CNS could be subclassified into PCG-like and FHC.
  • Although our cases did not show ALK immunoreactivity, some IMTs-CNS can recur, which suggests the neoplastic potential of these tumors.
  • The rearrangement of the ALK gene in IMTs-CNS should be verified by an examination of more cases.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Neoplasms, Muscle Tissue / complications. Neoplasms, Muscle Tissue / pathology
  • [MeSH-minor] Actins / metabolism. Adult. Aged. Female. Granuloma, Plasma Cell / metabolism. Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / physiopathology. Humans. Immunohistochemistry / methods. Inflammation / etiology. Inflammation / pathology. Magnetic Resonance Imaging / methods. Male. Middle Aged. Sex Factors. Staining and Labeling / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804057.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins
  •  go-up   go-down


35. Wang T, Hui XH, Zhou LX, Ju Y, Rong HT, Zhang Q: [Expression of CXCR4 and VEGF in hemangioblastomas of the central nervous system and its relation to tumor angiogenesis]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 May;41(3):420-3
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of CXCR4 and VEGF in hemangioblastomas of the central nervous system and its relation to tumor angiogenesis].
  • OBJECTIVE: To evaluate the relationships of CXCR4 (chemokine stromal cell-drived factor-1 receptor) and VEGF (vaseular endothelial growth factor) expression to tumor angiogenesis in hemangioblastomas of the central nervous system.
  • The endothelial cells of blood vessels within the tumor were labeled by CD34, then the microvessel density (MVD) was calculated.
  • CXCR4 expression was located in the nucleus of tumor stromal cells.
  • VEGF expression was located in the cytoplasm and membrane of tumor stromal cells and some endothelial cells.
  • But there is no significant difference between the cystic and solid tumors, VHL disease and sporadic disease on the expression level of CXCR4, VEGF and MVD (P > 0.05).
  • [MeSH-major] Brain Neoplasms / blood supply. Hemangioblastoma / blood supply. Neovascularization, Pathologic / metabolism. Receptors, CXCR4 / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629312.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCR4 protein, human; 0 / Receptors, CXCR4; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


36. Alameda F, Lloreta J, Ariza A, Salido M, Espinet B, Baro T, Garcia-Fructoso G, Galito E, Munne A, Cruz Sanchez FF, Sole F, Serrano S: Primitive neuroectodermal tumor of the central nervous system with glial differentiation: a FISH study of an adult case. Clin Neuropathol; 2007 Jan-Feb;26(1):12-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumor of the central nervous system with glial differentiation: a FISH study of an adult case.
  • Primitive neuroectodermal tumors (PNETs) of the central nervous system (CNS), a rare occurrence in adults, may show glial differentiation and can be misinterpreted as pure astrocytic neoplasms.
  • Few fluorescence in situ hybridization (FISH) studies have been carried out on these tumors; isochromosome 17q was found to be the major chromosomal abnormality.
  • We present the case of an adult in which we performed a FISH study of both the glial and neuronal components.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Chromosomes, Human, Pair 17 / genetics. Neuroectodermal Tumors, Primitive / genetics. Neuroectodermal Tumors, Primitive / pathology. Trisomy / genetics
  • [MeSH-minor] Adult. Humans. In Situ Hybridization, Fluorescence. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290931.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


37. Lee Y, Kim JH, Kim E, Park SH, Yim YJ, Sohn CH, Chang KH: Tumor-mimicking primary angiitis of the central nervous system: initial and follow-up MR features. Neuroradiology; 2009 Oct;51(10):651-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-mimicking primary angiitis of the central nervous system: initial and follow-up MR features.
  • INTRODUCTION: Primary angiitis of the central nervous system (PACNS) is an extremely rare vasculitis of unknown etiology.
  • The purpose of this study was to describe the initial and follow-up magnetic resonance (MR) imaging features of the tumor-mimicking PACNS.
  • METHODS: We retrospectively reviewed a total of 21 initial and follow-up brain MR images obtained in four patients with biopsy-proven PACNS mimicking brain tumor on MR images during the periods from 1 to 8.1 years.
  • CONCLUSION: Tumor-mimicking PACNS shows variable features on initial MR images but shows good responses to appropriate immunosuppressive therapy on follow-up MR images.
  • [MeSH-major] Brain / pathology. Vasculitis, Central Nervous System / pathology
  • [MeSH-minor] Adult. Brain Neoplasms / pathology. Cerebral Angiography. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Female. Follow-Up Studies. Humans. Immunosuppression. Immunosuppressive Agents / therapeutic use. Magnetic Resonance Angiography. Magnetic Resonance Spectroscopy. Male. Protons. Recurrence. Retrospective Studies. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19529928.001).
  • [ISSN] 1432-1920
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Protons
  •  go-up   go-down


38. Neder L, Scheithauer BW, Turel KE, Arnesen MA, Ketterling RP, Jin L, Moynihan TJ, Giannini C, Meyer FB: Desmoplastic small round cell tumor of the central nervous system: report of two cases and review of the literature. Virchows Arch; 2009 Apr;454(4):431-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic small round cell tumor of the central nervous system: report of two cases and review of the literature.
  • Desmoplastic small round cell tumor (DSRCT) is a malignant tumor often involving the abdominal and/or pelvic peritoneum.
  • Only one fully documented example has arisen in the central nervous system (CNS).
  • In conclusion, CNS DSRCT follows a similar aggressive course as do peritoneal examples.
  • Although rare, DSRCT warrants consideration in the differential diagnosis of "malignant small blue cell tumors" of the CNS.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Cerebellar Neoplasms / pathology. Cerebellopontine Angle / pathology
  • [MeSH-minor] Adult. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263077.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / EWS1-WT1 fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


39. Kowalewska B, Krywejko J, Roszkowska E: [Efficacy of rituximab in refractory Wegener's granulomatosis with central nervous system involvement]. Ann Acad Med Stetin; 2010;56 Suppl 1:99-104
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of rituximab in refractory Wegener's granulomatosis with central nervous system involvement].
  • Besides this classic triad of affected organs, less frequent manifestations of WG include involvement of the skin, central nervous system (CNS), and eyeballs (often with proptosis), as well as otitis with progressive hearing loss.
  • The frequency of CNS involvement according to various researchers lies between 4% and 11% of WG cases.
  • Dura mater infiltrates, cranial nerve pathology, and vasculitis are the most frequent CNS lesions.
  • Three major mechanisms have been implicated in CNS involvement accompanying WG: contiguous growth of granuloma from extracranial sites (e.g., paranasal sinuses), intracranial granuloma (tumor) formation, and vasculitis.
  • [MeSH-major] Antibodies, Monoclonal, Murine-Derived / therapeutic use. Granulomatosis with Polyangiitis / drug therapy. Granulomatosis with Polyangiitis / epidemiology. Nervous System Diseases / drug therapy. Nervous System Diseases / epidemiology
  • [MeSH-minor] Adult. Causality. Comorbidity. Female. Humans. Immunologic Factors / therapeutic use. Magnetic Resonance Imaging. Remission Induction. Rituximab

  • Genetic Alliance. consumer health - Wegener's granulomatosis.
  • MedlinePlus Health Information. consumer health - Granulomatosis with Polyangiitis.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21365953.001).
  • [ISSN] 1427-440X
  • [Journal-full-title] Annales Academiae Medicae Stetinensis
  • [ISO-abbreviation] Ann Acad Med Stetin
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


40. Wadasadawala T, Trivedi S, Gupta T, Epari S, Jalali R: The diagnostic dilemma of primary central nervous system melanoma. J Clin Neurosci; 2010 Aug;17(8):1014-1017
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic dilemma of primary central nervous system melanoma.
  • Melanomas are malignant neoplasms of melanocytes developing predominantly in the skin, but occasionally arising from eyes, mucous membranes, and the central nervous system (CNS).
  • The CNS can be affected by a spectrum of melanocytic lesions ranging from diffuse neurocutaneous melanosis, to a focal and benign neoplasm (melanocytoma), and to an overtly malignant tumor (melanoma).
  • Primary melanocytic lesions involving the CNS are typically concentrated in the perimedullary and high cervical region.
  • Primary CNS melanoma cannot be reliably distinguished from metastatic melanoma on neuroimaging and histopathological characteristics alone: its diagnosis is established only after exclusion of secondary metastatic disease from a cutaneous, mucosal or retinal primary.
  • We present two patients with primary CNS melanoma and discuss relevant issues, available treatment options, and expected outcomes.
  • Awareness of disease spectrum and clinico-biological differences may be used to guide therapeutic decision-making for a patient with a proven or suspected primary CNS melanoma.
  • [MeSH-major] Brain Neoplasms / pathology. Cerebellopontine Angle / pathology. Melanoma / pathology. Parietal Lobe / pathology
  • [MeSH-minor] Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20627582.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


41. Dietlein M, Pels H, Schulz H, Staak O, Borchmann P, Schomäcker K, Fischer T, Eschner W, Pogge von Strandmann E, Schicha H, Engert A, Schnell R: Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol; 2005 Apr;74(4):348-52
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of central nervous system lymphomas with iodine-123 labeled rituximab.
  • Most patients with primary central nervous system (CNS) lymphoma (PCNSL) relapse after initial response to chemotherapy or the combination of chemotherapy and irradiation.
  • As the majority of PCNSL are B-cell neoplasms expressing the CD20 antigen, treatment with the chimeric monoclonal antibody (MAb) rituximab might be reasonable.
  • Only one patient showed a very weak or questionable uptake of 123I-rituximab into tumor tissue which was ninefold lower compared with the blood-pool accumulation.
  • These data suggest that systemic MAb-based radio-immunotherapy is not feasible in patients with PCNSL because a sufficient activity in the tumor will be associated with severe hematotoxicity.
  • [MeSH-major] Antibodies, Monoclonal. Brain Neoplasms / radionuclide imaging. Lymphoma, B-Cell / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Radioimmunodetection
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Humans. Iodine Radioisotopes. Rituximab. Tomography, Emission-Computed, Single-Photon

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Blackwell Munksgaard.
  • (PMID = 15777348.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Iodine Radioisotopes; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


42. Lee VH, Connolly HM, Brown RD Jr: Central nervous system manifestations of cardiac myxoma. Arch Neurol; 2007 Aug;64(8):1115-20
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system manifestations of cardiac myxoma.
  • Potential delayed neurologic complications relevant to patients with tumor embolization include myxoma-induced cerebral aneurysm and myxomatous metastasis, which can mimic the clinical picture of central nervous system vasculitis or infective endocarditis.
  • [MeSH-major] Brain Diseases / etiology. Heart Neoplasms / complications. Myxoma / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Brain / radiography. Echocardiography, Transesophageal. Female. Heart Atria. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17698701.001).
  • [ISSN] 0003-9942
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Fuller CE, Perry A: Molecular diagnostics in central nervous system tumors. Adv Anat Pathol; 2005 Jul;12(4):180-94
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnostics in central nervous system tumors.
  • Central nervous system (CNS) neoplasms can be diagnostically challenging, due to remarkably wide ranges in histologic appearance, biologic behavior, and therapeutic approach.
  • In this regard, the field is primed by recent advances in basic research, elucidating the molecular mechanisms of tumorigenesis and progression in the most common adult and pediatric brain tumors.
  • Thus far, few have made the transition into routine clinical practice, the most notable example being 1p and 19q testing in oligodendroglial tumors.
  • The goal of this article is to highlight the most common genetic alterations currently implicated in CNS tumors, focusing most on those that are either already in common use in ancillary molecular diagnostics testing or are likely to become so in the near future.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Central Nervous System Neoplasms / genetics. Ependymoma / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Chromosome Aberrations. Humans. In Situ Hybridization, Fluorescence. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / genetics. Meningioma / diagnosis. Meningioma / genetics. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / genetics. Polymerase Chain Reaction. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096380.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 260
  •  go-up   go-down


44. Scalabrino G: The multi-faceted basis of vitamin B12 (cobalamin) neurotrophism in adult central nervous system: Lessons learned from its deficiency. Prog Neurobiol; 2009 Jul;88(3):203-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The multi-faceted basis of vitamin B12 (cobalamin) neurotrophism in adult central nervous system: Lessons learned from its deficiency.
  • Glial cells, myelin and the interstitium are the structures of the mammalian central nervous system (CNS) mainly affected by vitamin B(12) (cobalamin, Cbl) deficiency.
  • Surprisingly, rat Schwann cells (myelin-forming cells of the peripheral nervous system) are fully activated but the few oligodendrocytes (myelin-forming cells of the CNS) are scarcely activated.
  • The results obtained in the CNS of Cbl-deficient rats indicate that cytokine and growth factor imbalance is a key point in the pathogenesis of Cbl-deficient neuropathy.
  • In the rat, Cbl deficiency increases the spinal cord (SC) synthesis and CSF levels of myelinotoxic cytokines (tumor necrosis factor (TNF)-alpha and soluble (s) CD40:sCD40 ligand dyad) and a myelinotoxic growth factor (nerve growth factor), but decreases SC synthesis and CSF levels of a myelinotrophic cytokine (interleukin-6) and a myelinotrophic growth factor (epidermal growth factor, EGF).
  • The in vivo administration of IL-6 or EGF, or agents antagonizing the excess myelinotoxic agent, is as effective as Cbl in repairing or preventing Cbl-deficiency-induced CNS lesions.
  • [MeSH-major] Central Nervous System. Vitamin B 12 / metabolism. Vitamin B 12 Deficiency / metabolism. Vitamin B 12 Deficiency / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394404.001).
  • [ISSN] 1873-5118
  • [Journal-full-title] Progress in neurobiology
  • [ISO-abbreviation] Prog. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Intercellular Signaling Peptides and Proteins; P6YC3EG204 / Vitamin B 12
  • [Number-of-references] 137
  •  go-up   go-down


45. Kwak SP, Malberg JE, Howland DS, Cheng KY, Su J, She Y, Fennell M, Ghavami A: Ablation of central nervous system progenitor cells in transgenic rats using bacterial nitroreductase system. J Neurosci Res; 2007 May 1;85(6):1183-93
Hazardous Substances Data Bank. BROMODEOXYURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ablation of central nervous system progenitor cells in transgenic rats using bacterial nitroreductase system.
  • Specific ablation of central nervous system (CNS) progenitor cells in the brain of live animals is a powerful method to determine the functions of these cells and to reveal novel avenues for the treatment of several CNS-related disorders.
  • In this system, NTR(+) cells are selectively eliminated upon application of prodrug CB1954, through activation of programmed cell death machineries.
  • In adult rats, GFP expression was not seen in the hippocampal progenitor cells and seen only at very low levels in the lateral ventricles, indicating a different NTR/GFP expression pattern between neonates and adults.
  • [MeSH-major] Central Nervous System / cytology. Escherichia coli Proteins / metabolism. Nitroreductases / metabolism. Stem Cells / physiology
  • [MeSH-minor] Animals. Animals, Genetically Modified. Animals, Newborn. Antineoplastic Agents / pharmacology. Aziridines / pharmacology. Behavior, Animal / drug effects. Behavior, Animal / physiology. Bromodeoxyuridine / metabolism. Cell Line, Tumor. Dose-Response Relationship, Drug. Electroshock / adverse effects. Green Fluorescent Proteins / metabolism. Humans. Injections, Intraventricular / methods. Intermediate Filament Proteins / metabolism. Nerve Tissue Proteins / metabolism. Nestin. Rats. Rats, Sprague-Dawley. Time Factors

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17304579.001).
  • [ISSN] 0360-4012
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Aziridines; 0 / Escherichia coli Proteins; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, rat; 0 / Nestin; 147336-22-9 / Green Fluorescent Proteins; 7865D5D01M / tretazicar; EC 1.7.- / NfsA protein, E coli; EC 1.7.- / Nitroreductases; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


46. Ullrich S, Schinke S, Both M, Knop KC, Kirkiles-Smith NC, Gross WL, Lamprecht P: Refractory central nervous system vasculitis and gastrocnemius myalgia syndrome in Crohn's disease successfully treated with anti-tumor necrosis factor-alpha antibody. Semin Arthritis Rheum; 2009 Apr;38(5):337-47
MedlinePlus Health Information. consumer health - Muscle Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory central nervous system vasculitis and gastrocnemius myalgia syndrome in Crohn's disease successfully treated with anti-tumor necrosis factor-alpha antibody.
  • The first involves the central nervous system, while the second represents circumscribed Musculus gastrocnemius involvement (so-called "gastrocnemius myalgia syndrome").
  • Successful treatment of refractory secondary vasculitis in CD with an anti-tumor necrosis factor-alpha antibody is shown for the first time.
  • Treatment with an anti- tumor necrosis factor-alpha antibody may prove a treatment option in vasculitis as an extraintestinal manifestation of CD.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Antibodies, Monoclonal / administration & dosage. Crohn Disease / drug therapy. Muscular Diseases / drug therapy. Tumor Necrosis Factor-alpha / antagonists & inhibitors. Vasculitis, Central Nervous System / drug therapy
  • [MeSH-minor] Adalimumab. Adult. Antibodies, Monoclonal, Humanized. Drug Resistance. Female. Humans. Middle Aged. Muscle, Skeletal / blood supply

  • Genetic Alliance. consumer health - Crohn Disease.
  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18304612.001).
  • [ISSN] 1532-866X
  • [Journal-full-title] Seminars in arthritis and rheumatism
  • [ISO-abbreviation] Semin. Arthritis Rheum.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01HL51014; United States / NHLBI NIH HHS / HL / R01HL62188
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Tumor Necrosis Factor-alpha; FYS6T7F842 / Adalimumab
  • [Number-of-references] 76
  •  go-up   go-down


47. Shukla K, Parikh B, Shukla J, Trivedi P, Shah B: Accuracy of cytologic diagnosis of central nervous system tumours in crush preparation. Indian J Pathol Microbiol; 2006 Oct;49(4):483-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of cytologic diagnosis of central nervous system tumours in crush preparation.
  • The aim of this study was to assess the usefulness and accuracy of cytologic smears by making crush preparation as a diagnostic method, in central nervous system tumors.
  • 278 patients with central nervous system tumors were investigated.
  • The most common tumor in intracranial cavity was astrocytoma (56.68%), followed by meningioma (6.88%), medulloblastoma (5.66%) and ependymoma (5.56%).
  • The most common tumor in intraspinal cavity was ependymoma (38.46%), followed by meningioma (23.07%) and schwannoma (23.07%).
  • In conclusion, crush preparation is an effective, simple, rapid, relatively safe and reliable technique for the diagnosis of central nervous system tumors.
  • [MeSH-major] Astrocytoma. Central Nervous System Neoplasms / diagnosis. Cytodiagnosis. Ependymoma. Medulloblastoma. Meningioma. Neurilemmoma
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cytological Techniques / methods. Female. Humans. Male. Middle Aged. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17183833.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] India
  •  go-up   go-down


48. Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, Hudson MM, Donaldson SS, King AA, Stovall M, Krull KR, Robison LL, Packer RJ: Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst; 2009 Jul 1;101(13):946-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study.
  • BACKGROUND: Adult survivors of childhood central nervous system (CNS) malignancies are at high risk for long-term morbidity and late mortality.
  • However, patterns of late mortality, the long-term risks of subsequent neoplasms and debilitating medical conditions, and sociodemographic outcomes have not been comprehensively characterized for individual diagnostic and treatment groups.
  • METHODS: We collected information on treatment, mortality, chronic medical conditions, and neurocognitive functioning of adult 5-year survivors of CNS malignancies diagnosed between 1970 and 1986 within the Childhood Cancer Survivor Study.
  • Using competing risk framework, we calculated cumulative mortality according to cause of death and cumulative incidence of subsequent neoplasms according to exposure and dose of cranial radiation therapy (RT).
  • Neurocognitive impairment and socioeconomic outcomes were assessed with respect to dose of CNS radiotherapy to specific brain regions.
  • Patients who received cranial RT of 50 Gy or more (n = 813) had a cumulative incidence of a subsequent neoplasm within the CNS of 7.1% (95% CI = 4.5% to 9.6%) at 25 years from diagnosis compared with 1.0% (95% CI = 0% to 2.3%) for patients who had no RT.
  • Neurocognitive impairment was high and proportional to radiation dose for specific tumor types.
  • CONCLUSIONS: Survivors of childhood CNS malignancies are at high risk for late mortality and for developing subsequent neoplasms and chronic medical conditions.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 1994 Jul 16;309(6948):162-6 [8044095.001]
  • [Cites] J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79 [18812549.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Neurol. 2002 Aug;249(8):955-60 [12195437.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):663-73 [12548609.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1115-26 [12569614.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):279-87 [12892234.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] JAMA. 2003 Sep 24;290(12):1583-92 [14506117.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4731-9 [14557448.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Dec;20(8):617-25 [14578032.001]
  • [Cites] Neuropsychology. 2003 Oct;17(4):548-55 [14599268.001]
  • [Cites] Curr Opin Neurol. 2003 Dec;16(6):677-83 [14624076.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):999-1006 [15020603.001]
  • [Cites] Ann Fam Med. 2004 Jan-Feb;2(1):61-70 [15053285.001]
  • [Cites] Cancer. 2004 May 15;100(10):2246-52 [15139071.001]
  • [Cites] J Clin Epidemiol. 2004 Sep;57(9):933-44 [15504636.001]
  • [Cites] Am J Epidemiol. 1986 Jan;123(1):174-84 [3509965.001]
  • [Cites] Am J Clin Oncol. 1985 Dec;8(6):472-6 [3936349.001]
  • [Cites] Arch Dis Child. 1990 Dec;65(12):1356-63 [2270944.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):592-9 [2066756.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1397-406 [1517782.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2188-97 [18792068.001]
  • [Cites] Int J Epidemiol. 1998 Feb;27(1):91-5 [9563700.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1723-8 [9586884.001]
  • [Cites] Ann Neurol. 1998 Sep;44(3):313-6 [9749596.001]
  • [Cites] Med Pediatr Oncol. 1998 Dec;31(6):506-11 [9835903.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] J Neurooncol. 1999 Jan;41(1):47-53 [10222422.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1905-10 [15534607.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4979-90 [15576413.001]
  • [Cites] Pediatr Blood Cancer. 2005 Aug;45(2):155-61 [15880357.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):637-44 [16421901.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):83-8 [16317732.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2536-43 [16735706.001]
  • [Cites] Radiat Res. 2006 Jul;166(1 Pt 2):141-57 [16808603.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1084-91 [16870549.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(2):351-62 [17141498.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):460-7 [16767717.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1532-8 [17442996.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):47-51 [16755550.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4014-21 [18258798.001]
  • [Cites] Cancer. 2008 May 1;112(9):2071-9 [18327823.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):245-50 [18386785.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4401-9 [18802152.001]
  • [CommentIn] J Natl Cancer Inst. 2009 Jul 1;101(13):908-10 [19549957.001]
  • [CommentIn] J Natl Cancer Inst. 2009 Jul 1;101(13):909 [19549959.001]
  • (PMID = 19535780.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24-CA55727
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2704230
  •  go-up   go-down


49. Kułakowska A, Pogorzelski R, Drozdowski W: [Primary central nervous system lymphoma with initial symptoms suggesting herpes encephalitis]. Pol Merkur Lekarski; 2008 Jan;24(139):30-3
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary central nervous system lymphoma with initial symptoms suggesting herpes encephalitis].
  • Primary central nervous system lymphoma (PCNSL) is rare neoplasm, affecting both immunocompetent and immunodeficient patients.
  • It is usually seen as intracranial tumor, but it can often involve cerebrospinal meninges, eyeballs and spinal cord.
  • We described a case of 43 year old patient with diagnosed PCNSL and discussed clinical signs, diagnostics and treatment of the neoplasm.
  • [MeSH-major] Brain Neoplasms / diagnosis. Encephalitis, Herpes Simplex / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18634249.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


50. Lim M, Cheshier S, Steinberg GK: New vessel formation in the central nervous system during tumor growth, vascular malformations, and Moyamoya. Curr Neurovasc Res; 2006 Aug;3(3):237-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New vessel formation in the central nervous system during tumor growth, vascular malformations, and Moyamoya.
  • In the normal adult brain, blood vessel formation is tightly down-regulated.
  • However, pathologic processes such as brain tumors can increase the proportion of endothelial cells involved in angiogenesis.
  • In this review, we will describe the process of angiogenesis in the central nervous system.
  • We will also look into their significance in disease processes such as neoplasms, arteriovenous malformations (AVM), and Moyamoya disease.
  • [MeSH-major] Brain / blood supply. Brain Neoplasms / blood supply. Central Nervous System Vascular Malformations / pathology. Moyamoya Disease / pathology. Neovascularization, Pathologic. Neovascularization, Physiologic

  • Genetic Alliance. consumer health - Vascular Malformations.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918387.001).
  • [ISSN] 1567-2026
  • [Journal-full-title] Current neurovascular research
  • [ISO-abbreviation] Curr Neurovasc Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiopoietins; 0 / Integrins; 0 / Platelet-Derived Growth Factor; 0 / Vascular Endothelial Growth Factor A; 62031-54-3 / Fibroblast Growth Factors
  • [Number-of-references] 98
  •  go-up   go-down


51. Sakurada K, Saino M, Mouri W, Sato A, Kitanaka C, Kayama T: Nestin expression in central nervous system germ cell tumors. Neurosurg Rev; 2008 Apr;31(2):173-6; discussion 176-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in central nervous system germ cell tumors.
  • Central nervous system (CNS) germ cell tumors constitute a unique class of rare tumors that mainly affect children and adolescents.
  • These tumors are believed to originate from displaced primordial germ cells.
  • Recently, results of treatment of germ cell tumors have improved with use of radiotherapy and combination chemotherapy.
  • However, some tumors have proven refractory to intensive treatment with surgery, radiation, and combination chemotherapy.
  • Nestin is an intermediate filament protein expressed in undifferentiated cells during CNS development and in CNS tumors and is used as a marker of immature elements of tumors, including brain tumor stem cells.
  • In this study, we examined for the first time nestin expression in 19 CNS germ cell tumors (nine pure germinomas, five germinomas with syncytiotrophoblastic giant cells, one yolk sac tumor, one choriocarcinoma, one embryonal carcinoma, and two mature teratomas).
  • Clinically, nestin-negative tumors did not exhibit dissemination, while all tumors that exhibited dissemination also strongly expressed nestin protein.
  • These findings suggest that the detection of nestin expression could be useful in the management of CNS germ cell tumors, as an auxiliary predictor of dissemination and/or progression.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Central Nervous System Neoplasms / genetics. Intermediate Filament Proteins / biosynthesis. Intermediate Filament Proteins / genetics. Neoplasms, Germ Cell and Embryonal / genetics. Nerve Tissue Proteins / biosynthesis. Nerve Tissue Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Choriocarcinoma / genetics. Choriocarcinoma / metabolism. Choriocarcinoma / pathology. Endodermal Sinus Tumor / genetics. Endodermal Sinus Tumor / metabolism. Endodermal Sinus Tumor / pathology. Female. Germinoma / genetics. Germinoma / metabolism. Germinoma / pathology. Giant Cell Tumors / genetics. Giant Cell Tumors / metabolism. Giant Cell Tumors / pathology. Humans. Hypopituitarism / etiology. Immunoenzyme Techniques. Magnetic Resonance Imaging. Male. Nestin. Teratoma / genetics. Teratoma / metabolism. Teratoma / pathology. Vision Disorders / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18092184.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


52. Liu HY, Zhang XL, Chen YP, Qiu SJ: [Characteristic imaging features of primary central nervous system lymphoma in comparison with pathological findings]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Feb;29(2):333-6
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristic imaging features of primary central nervous system lymphoma in comparison with pathological findings].
  • OBJECTIVE: To investigate the imaging features of primary central nervous system lymphoma (PCNSL).
  • RESULTS: Among the 13 patients with PCNSL, 11 were identified to have solitary tumor foci and the other 2 had multiple lesions.
  • Supratentorial tumors were found in 9 patients, infratentorial tumors in 3 patients, and both supratentorial and infratentorial tumors in 1 patient.
  • In 6 cases, the tumor presented isodensity or slight hypodensity on plain CT images, with mild or moderate enhancement after contrast agent injection.
  • Pathologically, the tumors appeared pinkish or grey-white, soft, with rich blood supply and without capsules.
  • The tumor cells were found to cluster around the blood vessels under microscope.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis. Lymphoma / pathology. Magnetic Resonance Imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Supratentorial Neoplasms / diagnosis. Supratentorial Neoplasms / pathology. Young Adult

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246316.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


53. Koh ES, Nichol A, Millar BA, Ménard C, Pond G, Laperriere NJ: Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system. Int J Radiat Oncol Biol Phys; 2007 Dec 1;69(5):1521-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system.
  • PURPOSE: To assess the clinical outcomes and toxicity in patients receiving fractionated external beam radiotherapy (EBRT) for hemangioblastoma of the central nervous system, treated at two Canadian radiation oncology institutions.
  • METHODS AND MATERIALS: Between January 1980 and December 2004, the data of all patients receiving EBRT for central nervous system hemangioblastoma were retrospectively reviewed.
  • The patient, tumor, and treatment characteristics were collected and overall survival, disease-free survival, and EBRT-related toxicities assessed.
  • [MeSH-major] Cerebellar Neoplasms / radiotherapy. Hemangioblastoma / radiotherapy. Spinal Cord Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. British Columbia. Disease-Free Survival. Dose Fractionation. Female. Humans. Male. Middle Aged. Ontario. Radiation Injuries / complications. Retrospective Studies. von Hippel-Lindau Disease / complications

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17869023.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


54. Assanasen T, Shuangshoti S, Nilyai S, Wannakrairot P, Ruangvejvorachai P, Sawatdee R, Sangprakarn S: Overexpression of c-Myc in primary central nervous system lymphoma of Thais. J Med Assoc Thai; 2006 Sep;89 Suppl 3:S40-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of c-Myc in primary central nervous system lymphoma of Thais.
  • BACKGROUND: c-Myc protooncogenes have been implicated in the tumourigenesis of extracerebral lymphomas, however only afew studies on this oncogenic molecule have been available for primary central nervous system lymphoma (PCNSL).
  • OBJECTIVE: To determine the prevalence ofprotein overexpression and gene amplification of c-Myc in PCNSL and to correlate with histological and immunophenotypic subtypes of malignant lymphoma according to WHO classification of tumors of haematopoietic and lymphoid tissue 2001.
  • [MeSH-major] Central Nervous System Neoplasms / metabolism. Lymphoma / metabolism. Proto-Oncogene Proteins c-myc / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Gene Amplification. Gene Expression Regulation, Neoplastic. Humans. Immunocompetence. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Prevalence. Thailand

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17718267.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


55. Iizuka N, Okamoto K, Matsushita R, Kimura M, Nagai K, Arito M, Kurokawa MS, Masuko K, Suematsu N, Hirohata S, Kato T: Identification of autoantigens specific for systemic lupus erythematosus with central nervous system involvement. Lupus; 2010 May;19(6):717-26
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of autoantigens specific for systemic lupus erythematosus with central nervous system involvement.
  • Using proteomic analysis, we identified candidate autoantigens specific for central nervous system (CNS) involvement in systemic lupus erythematosus (SLE).
  • Western blot analysis was performed using serum samples from 30 SLE patients with CNS involvement (CNS-Lupus) and from 30 SLE patients without CNS involvement (non-CNS-SLE).
  • On the 1-DE Western blot, we detected 32 antigenic bands in the serum samples from the CNS-Lupus patients.
  • Among them, four bands were detected significantly more frequently in the CNS-Lupus patients than in the non-CNS-SLE patients.
  • Three bands were detected in four or more of the CNS-Lupus patients but in only one or none of the non-CNS-SLE patients.
  • These four candidate autoantigens for the anti-neuronal cell antibodies would be a useful marker for CNS-Lupus.
  • [MeSH-major] Autoantigens / immunology. Lupus Vasculitis, Central Nervous System / immunology
  • [MeSH-minor] Adult. Autoantibodies / blood. Autoantibodies / immunology. Biomarkers / blood. Cell Line, Tumor. Electrophoresis, Gel, Two-Dimensional. Female. Histones / immunology. Humans. Male. Middle Aged. Neuroblastoma. Peroxiredoxins / immunology. RNA-Binding Proteins / immunology. Ubiquitin Thiolesterase / immunology. Young Adult

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026524.001).
  • [ISSN] 1477-0962
  • [Journal-full-title] Lupus
  • [ISO-abbreviation] Lupus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; 0 / Biomarkers; 0 / Histones; 0 / RNA-Binding Proteins; 0 / SRSF3 protein, human; EC 1.11.1.15 / PRDX4 protein, human; EC 1.11.1.15 / Peroxiredoxins; EC 3.1.2.15 / UCHL1 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  •  go-up   go-down


56. D'Haene N, Catteau X, Maris C, Martin B, Salmon I, Decaestecker C: Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas. Br J Haematol; 2008 Feb;140(4):402-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas.
  • Recently, considerable attention has been focused on the identification of clinically relevant prognostic markers for primary central nervous system lymphomas (PCNSL).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Central Nervous System Neoplasms / metabolism. Endothelium, Vascular / pathology. Galectin 3 / metabolism. Lymphoma, Non-Hodgkin / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Galectin 1 / metabolism. Humans. Hyperplasia / metabolism. Immunocompetence. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Proteins / metabolism. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18081894.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 1; 0 / Galectin 3; 0 / Neoplasm Proteins
  •  go-up   go-down


57. Kenai H, Yamashita M, Nakamura T, Asano T, Momii Y, Nagatomi H: Gamma Knife surgery for primary central nervous system lymphoma: usefulness as palliative local tumor control. J Neurosurg; 2006 Dec;105 Suppl:133-8
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery for primary central nervous system lymphoma: usefulness as palliative local tumor control.
  • OBJECT: Although there is no established treatment for primary central nervous system lymphoma (PCNSL), therapeutic protocols involving high-dose methotrexate therapy followed, in some cases, by whole-brain radiotherapy (WBRT) have generally been adopted, and they have yielded relatively favorable results.
  • In these patients, the mean tumor volume was 4.14 cm3, and the tumors were treated with a mean margin dose of 16.5 Gy to the 52.8% isodose line.
  • CONCLUSIONS: Gamma Knife surgery should be performed only for local tumor control as a stopgap measure in the treatment of PCNSL.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Lymphoma / pathology. Lymphoma / surgery. Palliative Care. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Tumor Burden. Young Adult


58. Kim EY, Kim SS: Magnetic resonance findings of primary central nervous system T-cell lymphoma in immunocompetent patients. Acta Radiol; 2005 Apr;46(2):187-92
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance findings of primary central nervous system T-cell lymphoma in immunocompetent patients.
  • PURPOSE: To describe the MR findings of primary central nervous system T-cell lymphoma (T-PCNSL) in immunocompetent patients.
  • The number, location, shape, enhancement pattern, and signal intensity of the tumors were determined.
  • All tumors showed iso- to low T1 and iso- to slightly high T2 signal intensity to the adjacent gray matter.
  • The lower rCBV ratio of the tumor might be helpful in differentiating T-PCNSL from other brain tumors such as high-grade glioma.
  • [MeSH-major] Brain Neoplasms / pathology. Immunocompetence. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Adolescent. Adult. Cerebrovascular Circulation / physiology. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Female. Humans. Male. Middle Aged. Reproducibility of Results

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902895.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


59. Ulu EM, Töre HG, Bayrak A, Güngör D, Coşkun M: MRI of central nervous system abnormalities in childhood leukemia. Diagn Interv Radiol; 2009 Jun;15(2):86-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI of central nervous system abnormalities in childhood leukemia.
  • PURPOSE: To document the imaging abnormalities seen in the central nervous system (CNS) in childhood leukemia or as complications of its treatment.
  • The first group consisted of patients with CNS abnormalities detected prior to or during treatment, or within three months after completion of treatment.
  • Patients with CNS complications detected by MRI three months following completion of treatment were included in the second group.
  • RESULTS: Among the 15 children, six had two or more different CNS abnormalities.
  • Three months after completion of treatment, three patients had CNS complications including radiation necrosis and secondary brain tumor, osteomyelitis of the L3 vertebra, and meningeal leukemia.
  • CONCLUSION: The wide spectrum of CNS abnormalities that occur during and after treatment for leukemia is related to leukemia and to the treatment method.
  • [MeSH-major] Central Nervous System Diseases / diagnosis. Central Nervous System Neoplasms / diagnosis. Leukemia / complications. Magnetic Resonance Imaging. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy / adverse effects. Female. Humans. Infant. Male. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517377.001).
  • [ISSN] 1305-3612
  • [Journal-full-title] Diagnostic and interventional radiology (Ankara, Turkey)
  • [ISO-abbreviation] Diagn Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


60. Plesec TP, Prayson RA: Frozen section discrepancy in the evaluation of central nervous system tumors. Arch Pathol Lab Med; 2007 Oct;131(10):1532-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frozen section discrepancy in the evaluation of central nervous system tumors.
  • CONTEXT: Frozen section (FS) evaluation of central nervous system (CNS) lesions provides an assessment of specimen adequacy and facilitates triage for ancillary studies.
  • DESIGN: All CNS FS cases involving a tumor diagnosis at FS or permanent section (N = 2156) from September 1997 until June 2005 were retrospectively reviewed.
  • Nine (15.8%) of 57 discrepancies involved errors in the diagnosis of CNS lymphoma.
  • Four (7.0%) of 57 discrepancies involved errors in the overgrading of tumors.
  • CONCLUSIONS: Frozen section of CNS neoplastic processes can be highly accurate.
  • Approximately 80% of the discrepant cases were classified into 5 categories: spindle cell lesions, astrocytoma versus oligodendroglioma, differential diagnosis of CNS lymphoma, reactive versus neoplastic process, and tumor overgrading.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Diagnostic Errors / statistics & numerical data. Frozen Sections / methods. Pathology, Surgical / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Intraoperative Period. Male. Middle Aged. Reproducibility of Results. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922589.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


61. Catapano D, Muscarella LA, Guarnieri V, Zelante L, D'Angelo VA, D'Agruma L: Hemangioblastomas of central nervous system: molecular genetic analysis and clinical management. Neurosurgery; 2005 Jun;56(6):1215-21; discussion 1221
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangioblastomas of central nervous system: molecular genetic analysis and clinical management.
  • OBJECTIVE: Hemangioblastomas of the central nervous system (CNS) are benign neoplasms that may occur sporadically or in association with von Hippel-Lindau (VHL) disease.
  • We investigated the frequency of VHL germline mutation in patients with symptomatic CNS hemangioblastoma without evidence of VHL disease to define the role of molecular genetic analysis in the management of such patients and their relatives.
  • METHODS: We analyzed 14 patients (6 female and 8 male; mean age, 43.5 yr) with no family history and no other clinical manifestations of VHL disease who had been operated on for symptomatic CNS hemangioblastoma.
  • CONCLUSION: Molecular genetic analysis is a safer and more specific instrument to confirm or exclude VHL disease in patients with CNS hemangioblastoma, a negative family history, or absence of other known manifestations of the disease.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Hemangioblastoma / genetics. Molecular Biology. Von Hippel-Lindau Tumor Suppressor Protein / genetics
  • [MeSH-minor] Adult. Aged. Arginine / genetics. DNA Mutational Analysis / methods. Exons. Female. Humans. Leucine / genetics. Magnetic Resonance Imaging / methods. Male. Middle Aged. Mutation, Missense. Proline / genetics. Retrospective Studies. Tryptophan / genetics. von Hippel-Lindau Disease / genetics

  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. L-Leucine .
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918937.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8DUH1N11BX / Tryptophan; 94ZLA3W45F / Arginine; 9DLQ4CIU6V / Proline; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein; GMW67QNF9C / Leucine
  •  go-up   go-down


62. Levy O, Deangelis LM, Filippa DA, Panageas KS, Abrey LE: Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer; 2008 Jan 1;112(1):151-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-6 predicts improved prognosis in primary central nervous system lymphoma.
  • BACKGROUND: In systemic non-Hodgkin lymphoma (NHL), tumors that resemble germinal center B-cells are less aggressive than tumors that resemble postgerminal center B-cells.
  • However, the value of B-cell differentiation markers in primary central nervous system lymphoma (PCNSL) is less clear.
  • There was a nonsignificant trend toward improved overall survival in patients who had bcl-6 expressing tumors.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis. Proto-Oncogene Proteins c-bcl-6 / analysis
  • [MeSH-minor] Adult. Age Factors. Aged. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17999414.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-6
  •  go-up   go-down


63. Metellus P, Bouvier C, Guyotat J, Fuentes S, Jouvet A, Vasiljevic A, Giorgi R, Dufour H, Grisoli F, Figarella-Branger D: Solitary fibrous tumors of the central nervous system: clinicopathological and therapeutic considerations of 18 cases. Neurosurgery; 2007 Apr;60(4):715-22; discussion 722
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumors of the central nervous system: clinicopathological and therapeutic considerations of 18 cases.
  • OBJECTIVE: This is a retrospective study of 18 patients harboring a solitary fibrous tumor of the central nervous system.
  • METHODS: Between 1999 and 2004, 18 patients harboring central nervous system solitary fibrous tumors were surgically treated at our two institutions.
  • Gross total resection was achieved in 10 cases (55.6%); tumor recurrence or progression occurred in nine cases (50%).
  • CONCLUSION: Prognosis of solitary fibrous tumors of the central nervous system remains unclear; consequently, careful and close monitoring of patients and long-term follow-up are mandatory.
  • In other respects, the role of postoperative radiotherapy in atypical or incompletely resected solitary fibrous tumors of the central nervous system remains to be determined and, therefore, warrants larger series with longer follow-up periods.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Neoplasms, Fibrous Tissue / radiotherapy. Neoplasms, Fibrous Tissue / surgery. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415209.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Kim SH, Cheong JW, Park KH, Kim TS, Yang WI: Comparison of ataxia-telangiectasia mutated protein expression in diffuse large B-cell lymphomas of primary central nervous system and non-central nervous system origin. Arch Pathol Lab Med; 2007 Mar;131(3):457-67
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of ataxia-telangiectasia mutated protein expression in diffuse large B-cell lymphomas of primary central nervous system and non-central nervous system origin.
  • In primary central nervous system diffuse large B-cell lymphomas (PCNS DLBCLs), the pathogenetic role of ATM mutation has not been investigated.
  • OBJECTIVE: To investigate ATM protein expression in PCNS DLBCLs, in comparison with that in non-central nervous system (non-CNS) DLBCLs and to study the relationship of ATM protein loss with several clinicopathologic parameters.
  • DESIGN: This study included 42 cases of PCNS DLBCL and 33 cases of non-CNS DLBCL from immunocompetent patients.
  • RESULTS: The loss of ATM expression was statistically more frequent in PCNS DLBCLs (21/42 cases [50.0%]) than in non-CNS DLBCLs (0/33 cases [0.0%]; P < .001).
  • CONCLUSIONS: Our results suggest that the ATM protein is more strongly correlated with PCNS DLBCL lymphomagenesis than with non-CNS DLBCLs, especially in germinal center B-cell-like subtypes demonstrating low Ki-67 labeling indexes and low Bcl-2 expression.
  • [MeSH-major] Cell Cycle Proteins / metabolism. Central Nervous System Neoplasms / metabolism. DNA-Binding Proteins / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Protein-Serine-Threonine Kinases / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Ataxia Telangiectasia Mutated Proteins. Child. Child, Preschool. Epstein-Barr Virus Infections / diagnosis. Female. Humans. In Situ Hybridization. Male. Middle Aged. Prognosis. RNA, Messenger / analysis. RNA-Binding Proteins / genetics. Ribosomal Proteins / genetics

  • Genetic Alliance. consumer health - Ataxia.
  • Genetic Alliance. consumer health - Ataxia Telangiectasia.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17516749.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / Tumor Suppressor Proteins; 135844-68-7 / RPL22 protein, human; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


65. Shibamoto Y, Ogino H, Hasegawa M, Suzuki K, Nishio M, Fujii T, Kato E, Ishihara S, Sougawa M, Kenjo M, Kawamura T, Hayabuchi N: Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):809-13
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s.
  • PURPOSE: Results of radiation therapy for primary central nervous system lymphoma (PCNSL) were poor in the 1970-1980s, with most reported 5-year survival rates being less than 10%.
  • The data were analyzed in relation to patient and tumor characteristics.
  • Multiple tumors were seen in 34%.
  • The median radiation dose to the tumor site was 50 Gy (range, 8-74 Gy).
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Lymphoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Multivariate Analysis. Survival Rate / trends

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936564.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


66. Yasuda K, Taguchi H, Sawamura Y, Ikeda J, Aoyama H, Fujieda K, Ishii N, Kashiwamura M, Iwasaki Y, Shirato H: Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system. Jpn J Clin Oncol; 2008 Jul;38(7):486-92
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system.
  • OBJECTIVE: The current study was conducted to evaluate the effects of low-dose craniospinal irradiation (CSI) combined with chemotherapy on non-metastatic embryonal tumors in the central nervous system (CNS), including medulloblastoma and supra-tentorial primitive neuroectodermal tumors (ST-PNET).
  • The dose to the primary tumor bed was 39.6-54 Gy.
  • CONCLUSION: Low-dose CSI and ICE chemotherapy may have a role as a treatment option for a subset of patients with non-metastatic embryonal tumors in the CNS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / therapy. Cranial Irradiation. Medulloblastoma / therapy. Neuroectodermal Tumors, Primitive / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Radiation. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Infant. Male. Radiotherapy Dosage. Supratentorial Neoplasms / pathology. Supratentorial Neoplasms / therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18573848.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


67. Montesinos-Rongen M, Schmitz R, Courts C, Stenzel W, Bechtel D, Niedobitek G, Blümcke I, Reifenberger G, von Deimling A, Jungnickel B, Wiestler OD, Küppers R, Deckert M: Absence of immunoglobulin class switch in primary lymphomas of the central nervous system. Am J Pathol; 2005 Jun;166(6):1773-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of immunoglobulin class switch in primary lymphomas of the central nervous system.
  • Primary lymphomas of the central nervous system (PCNSLs) were investigated for their capacity to perform further maturation steps.
  • This finding was corroborated at the protein level by the immunohistochemical demonstration of IgM on the surface of the tumor cells.
  • This may indicate that ongoing somatic mutation, which is often observed in PCNSL, could be due to sustained AID expression in a fraction of cases and that intraclonal V gene diversity may occur in other cases at an earlier phase of tumor clone expansion, when AID may have been expressed.
  • [MeSH-major] Central Nervous System Neoplasms / immunology. Immunoglobulin Class Switching. Lymphoma / immunology
  • [MeSH-minor] Adult. Aged. Cytidine Deaminase. Cytosine Deaminase / biosynthesis. Female. Gene Rearrangement, B-Lymphocyte, Heavy Chain / immunology. Humans. Immunohistochemistry. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Sep 1;102(5):553-63 [11007474.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2077-86 [10595937.001]
  • [Cites] Trends Immunol. 2002 Jan;23(1):31-9 [11801452.001]
  • [Cites] Annu Rev Immunol. 2002;20:165-96 [11861601.001]
  • [Cites] FEBS Lett. 2002 May 8;518(1-3):119-23 [11997030.001]
  • [Cites] Curr Treat Options Oncol. 2001 Aug;2(4):309-18 [12057111.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Oct;61(10):926-33 [12387458.001]
  • [Cites] Leukemia. 2003 Jan;17(1):260-6 [12529691.001]
  • [Cites] Blood. 2003 May 1;101(9):3574-80 [12511417.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3894-8 [12873980.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1869-75 [14592832.001]
  • [Cites] J Immunol. 1995 Mar 1;154(5):2237-47 [7868897.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1288-98 [9028952.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):1021-35 [9060839.001]
  • [Cites] Mol Immunol. 1996 Dec;33(17-18):1335-43 [9171893.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2145-57 [9498752.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3555-61 [9531318.001]
  • [Cites] Immunol Rev. 1998 Apr;162:261-80 [9602370.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2871-8 [9763572.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1679-89 [9802980.001]
  • [Cites] J Immunol. 1998 Nov 15;161(10):5217-25 [9820493.001]
  • [Cites] J Biol Chem. 1999 Jun 25;274(26):18470-6 [10373455.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1738-46 [10477699.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3318-25 [15304391.001]
  • [Cites] J Pathol. 2005 Apr;205(5):541-7 [15732141.001]
  • [Cites] J Neurol Sci. 2000 Dec 1;181(1-2):1-12 [11099705.001]
  • (PMID = 15920162.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.1 / Cytosine Deaminase; EC 3.5.4.5 / Cytidine Deaminase
  • [Other-IDs] NLM/ PMC1602401
  •  go-up   go-down


68. Guan YG, Wang TH, Ni W, Li L, Lu YC, Gao ZY: [Distribution of Fas and FasL in the central nervous system of adult rhesus]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 May;36(3):322-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distribution of Fas and FasL in the central nervous system of adult rhesus].
  • OBJECTIVE: To investigate the distribution of Fas and FasL in the CNS of adult rhesus.
  • CONCLUSION: The distribution profiles of Fas and FasL in various areas of CNS indicate that they may fill some roles in the immune and physical function of the aforesaid anatomic
  • [MeSH-major] Antigens, CD95 / metabolism. Brain Chemistry. Membrane Glycoproteins / metabolism. Tumor Necrosis Factors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15931857.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Tumor Necrosis Factors
  •  go-up   go-down


69. Saddawi-Konefka R, Crawford JR: Chronic viral infection and primary central nervous system malignancy. J Neuroimmune Pharmacol; 2010 Sep;5(3):387-403

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic viral infection and primary central nervous system malignancy.
  • Primary central nervous system (CNS) tumors cause significant morbidity and mortality in both adults and children.
  • In primary CNS malignancies, two families of viruses, namely polyomavirus and herpesvirus, have been detected with varied frequencies in a number of pediatric and adult histological tumor subtypes.
  • However, establishing a link between chronic viral infection and primary CNS malignancy has been an area of considerable controversy, due in part to variations in detection frequencies and methodologies used among researchers.
  • Since a latent viral neurotropism can be seen with a variety of viruses and a widespread seropositivity exists among the population, it has been difficult to establish an association between viral infection and CNS malignancy based on epidemiology alone.
  • The overall goals of this review are to summarize the many human investigations that have studied viral infection in primary CNS tumors, discuss potential neuro-oncomodulatory mechanisms of viral-associated CNS disease and propose future research directions to establish a more firm association between chronic viral infections and primary CNS malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2009 Jan 2;323(5910):30-1 [19119195.001]
  • [Cites] Indian J Pathol Microbiol. 2009 Jan-Mar;52(1):42-5 [19136778.001]
  • [Cites] Virology. 2009 Feb 20;384(2):266-73 [18995875.001]
  • [Cites] Virology. 2009 Feb 20;384(2):294-303 [19070883.001]
  • [Cites] J Natl Cancer Inst. 2009 Apr 1;101(7):488-97 [19318640.001]
  • [Cites] Folia Microbiol (Praha). 2003;48(3):291-318 [12879740.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5192-200 [12910256.001]
  • [Cites] Pathology. 2003 Jun;35(3):248-53 [14506971.001]
  • [Cites] Curr Top Microbiol Immunol. 2004;273:215-44 [14674603.001]
  • [Cites] Trends Mol Med. 2004 Jan;10(1):19-23 [14720582.001]
  • [Cites] FEMS Microbiol Rev. 2004 Feb;28(1):59-77 [14975530.001]
  • [Cites] Virology. 2004 Jan 5;318(1):1-9 [15015494.001]
  • [Cites] Cell Mol Life Sci. 2004 Jun;61(11):1307-16 [15170509.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):387-96 [15288264.001]
  • [Cites] Herpes. 2004 Jun;11 Suppl 2:120A-127A [15319099.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):768-76 [15728809.001]
  • [Cites] Apoptosis. 2005 Mar;10(2):251-65 [15843887.001]
  • [Cites] Am J Epidemiol. 2005 May 15;161(10):929-38 [15870157.001]
  • [Cites] J Neurosurg. 2005 Apr;102(3 Suppl):294-8 [15881753.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):838-43 [15578071.001]
  • [Cites] J Virol. 2003 Jun;77(12):7007-16 [12768019.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):140-2; author reply 143-5 [12794770.001]
  • [Cites] J Med Virol. 2003 Sep;71(1):115-23 [12858417.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4181-7 [12874024.001]
  • [Cites] Nature. 2003 Jul 24;424(6947):456-61 [12879076.001]
  • [Cites] Am J Pathol. 1999 Jul;155(1):285-92 [10393860.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11519-24 [10500209.001]
  • [Cites] Proc Soc Exp Biol Med. 1962 Nov;111:343-4 [14002172.001]
  • [Cites] Clin Microbiol Rev. 2005 Jan;18(1):217-45 [15653828.001]
  • [Cites] Br J Cancer. 2005 Feb 28;92(4):747-50 [15700045.001]
  • [Cites] J Cell Physiol. 2005 Aug;204(2):402-6 [15690396.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7951-7 [16258095.001]
  • [Cites] Brain Res Brain Res Rev. 2005 Dec 1;50(1):69-85 [15982744.001]
  • [Cites] Acta Neuropathol. 2006 Apr;111(4):388-96 [16557392.001]
  • [Cites] Adv Exp Med Biol. 2006;577:1-18 [16626024.001]
  • [Cites] Adv Exp Med Biol. 2006;577:310-8 [16626045.001]
  • [Cites] Adv Exp Med Biol. 2006;577:319-41 [16626046.001]
  • [Cites] Adv Exp Med Biol. 2006;577:342-56 [16626047.001]
  • [Cites] Sci STKE. 2006 May 16;2006(335):re4 [16705130.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):724-30 [18245472.001]
  • [Cites] Science. 1978 Sep 29;201(4362):1246-9 [211583.001]
  • [Cites] Acta Neurochir (Wien). 1978;43(3-4):239-49 [212932.001]
  • [Cites] Neurology. 1979 Dec;29(12):1590-4 [228217.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6446-50 [6273871.001]
  • [Cites] Prog Clin Biol Res. 1983;105:227-37 [6304760.001]
  • [Cites] J Virol. 1984 Mar;49(3):848-56 [6321769.001]
  • [Cites] J Neurovirol. 2006 Apr;12(2):90-9 [16798670.001]
  • [Cites] Pediatr Infect Dis J. 2006 Sep;25(9):841-2 [16940845.001]
  • [Cites] J Neurovirol. 2007;13(1):85; author reply 86-7 [17454453.001]
  • [Cites] J Virol. 2007 Jul;81(14):7629-35 [17494079.001]
  • [Cites] Yale J Biol Med. 2006 Dec;79(3-4):115-22 [17940621.001]
  • [Cites] J Neurooncol. 2007 Dec;85(3):271-80 [17589804.001]
  • [Cites] J Virol. 2000 Feb;74(3):1158-67 [10627526.001]
  • [Cites] J Clin Pathol. 1999 Aug;52(8):620-3 [10645234.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):85-92 [10668898.001]
  • [Cites] Hum Pathol. 2000 Mar;31(3):394-5 [10746685.001]
  • [Cites] Tissue Antigens. 2000 May;55(5):412-21 [10885561.001]
  • [Cites] J Infect Dis. 2000 Sep;182(3):643-51 [10950755.001]
  • [Cites] Ann Neurol. 2000 Dec;48(6):932-6 [11117551.001]
  • [Cites] J Med Virol. 2001 Jan;63(1):45-51 [11130886.001]
  • [Cites] J Gen Virol. 2001 Mar;82(Pt 3):493-7 [11172089.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):1-10 [11227065.001]
  • [Cites] Semin Cancer Biol. 2001 Feb;11(1):49-61 [11243899.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4287-93 [11358858.001]
  • [Cites] J Virol. 2001 Jul;75(13):6022-32 [11390604.001]
  • [Cites] Neuropathology. 2001 Jun;21(2):129-37 [11396678.001]
  • [Cites] Acta Vet Hung. 2000;48(4):477-84 [11402664.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7829-34 [11427719.001]
  • [Cites] Am J Epidemiol. 2001 Jul 15;154(2):161-5 [11447050.001]
  • [Cites] J Neurosurg. 2001 Jul;95(1):96-101 [11453404.001]
  • [Cites] Mol Pathol. 2001 Oct;54(5):331-7 [11577176.001]
  • [Cites] Dis Markers. 2001;17(3):149-51 [11790879.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1141-9 [11850833.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 20;94(4):267-73 [11854388.001]
  • [Cites] J Med Virol. 2002 Apr;66(4):497-505 [11857528.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2836-41 [11867723.001]
  • [Cites] J Virol. 2002 Apr;76(8):3731-8 [11907212.001]
  • [Cites] Neurology. 2002 Mar 26;58(6):895-900 [11914404.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3347-50 [12067971.001]
  • [Cites] Neuro Oncol. 2002 Jul;4(3):165-70 [12084346.001]
  • [Cites] Int J Cancer. 2002 Oct 1;101(4):348-52 [12209959.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] J Virol. 2002 Dec;76(24):12803-12 [12438605.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):957-64 [12459734.001]
  • [Cites] J Virol. 2003 Jan;77(1):631-41 [12477866.001]
  • [Cites] J Virol. 2003 Mar;77(5):2807-18 [12584304.001]
  • [Cites] J Virol. 2003 May;77(9):5039-45 [12692206.001]
  • [Cites] J Neurovirol. 2003 Apr;9(2):173-82 [12707848.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):460-3 [12750243.001]
  • [Cites] Neuro Oncol. 2008 Feb;10(1):10-8 [17951512.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):247-50 [18449881.001]
  • [Cites] Brain Res. 2008 Jul 24;1221:108-14 [18565499.001]
  • [Cites] Acta Neuropathol. 2008 Jul;116(1):79-86 [18351367.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):539-41 [18669440.001]
  • [Cites] J Clin Microbiol. 2008 Aug;46(8):2700-6 [18550745.001]
  • [Cites] Pediatrics. 2008 Sep;122(3):513-20 [18762520.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):391-5 [18701889.001]
  • [Cites] Cancer. 2008 Oct 1;113(7 Suppl):1953-68 [18798534.001]
  • [Cites] Ann Neurol. 2008 Oct;64(4):379-87 [18688812.001]
  • [Cites] Br J Cancer. 2009 Apr 21;100(8):1292-302 [19293793.001]
  • [Cites] Med Microbiol Immunol. 2009 May;198(2):79-81 [19198878.001]
  • [Cites] Semin Cancer Biol. 2009 Aug;19(4):270-5 [19416753.001]
  • [Cites] Semin Cancer Biol. 2009 Aug;19(4):252-60 [19505653.001]
  • [Cites] Semin Cancer Biol. 2009 Aug;19(4):261-9 [19505654.001]
  • [Cites] Rev Med Virol. 2009 Jul;19(4):185-99 [19530118.001]
  • [Cites] PLoS Pathog. 2009 Jul;5(7):e1000523 [19649277.001]
  • [Cites] J Clin Virol. 2009 Sep;46(1):37-42 [19505845.001]
  • [Cites] J Neurooncol. 2009 Oct;95(1):49-60 [19424665.001]
  • [Cites] Herpes. 2008 Nov;15(2):28-32 [19856545.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38325-30 [15247271.001]
  • [Cites] Lancet. 1971 Jun 19;1(7712):1253-7 [4104714.001]
  • [Cites] Lancet. 1971 Jun 19;1(7712):1257-60 [4104715.001]
  • [Cites] Science. 1973 Aug 17;181(4100):674-6 [4353360.001]
  • [Cites] Int J Cancer. 1978 Jan 15;21(1):12-7 [203540.001]
  • [Cites] Virology. 1984 Jul 30;136(2):359-67 [6087549.001]
  • [Cites] J Gen Virol. 1986 Sep;67 ( Pt 9):1759-816 [3018124.001]
  • [Cites] Int J Cancer. 1987 Jan 15;39(1):60-7 [3025111.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jan;84(1):16-20 [3025851.001]
  • [Cites] Virology. 1987 Sep;160(1):268-70 [2820135.001]
  • [Cites] Lancet. 1988 May 14;1(8594):1065-7 [2896909.001]
  • [Cites] J Gen Virol. 1988 Jul;69 ( Pt 7):1531-74 [2839594.001]
  • [Cites] J Clin Microbiol. 1989 Apr;27(4):651-3 [2542358.001]
  • [Cites] Mol Cell Biol. 1990 Jan;10(1):120-30 [2136765.001]
  • [Cites] J Cell Biochem. 1990 Jan;42(1):13-31 [2153691.001]
  • [Cites] J Gen Virol. 1990 Nov;71 ( Pt 11):2731-6 [2174963.001]
  • [Cites] Virology. 1991 Jan;180(1):49-57 [1845837.001]
  • [Cites] Adv Cancer Res. 1991;57:47-85 [1835254.001]
  • [Cites] N Engl J Med. 1992 Apr 9;326(15):988-93 [1312224.001]
  • [Cites] J Virol. 1994 Jun;68(6):3917-24 [8189528.001]
  • [Cites] N Engl J Med. 1994 Aug 18;331(7):432-8 [8035839.001]
  • [Cites] J Neurooncol. 1994;20(1):55-8 [7807184.001]
  • [Cites] Int J Cancer. 1995 Jun 9;61(6):756-60 [7790107.001]
  • [Cites] Virology. 1995 Oct 1;212(2):710-7 [7571441.001]
  • [Cites] J Virol. 1995 Nov;69(11):6697-704 [7474079.001]
  • [Cites] J Med Virol. 1995 Sep;47(1):105-11 [8551252.001]
  • [Cites] J Virol. 1996 Apr;70(4):2378-86 [8642665.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7352-7 [8692997.001]
  • [Cites] Virology. 1996 Aug 15;222(2):365-74 [8806520.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4820-5 [8841004.001]
  • [Cites] Oncogene. 1997 Jan 23;14(3):359-67 [9018122.001]
  • [Cites] Intervirology. 1996;39(4):259-69 [9078467.001]
  • [Cites] Am J Epidemiol. 1997 Apr 1;145(7):594-7 [9098175.001]
  • [Cites] J Neurovirol. 1997 May;3 Suppl 1:S78-9 [9179802.001]
  • [Cites] J Virol. 1997 Jul;71(7):5620-3 [9188637.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2054-61 [9329970.001]
  • [Cites] J Gen Virol. 1997 Dec;78 ( Pt 12):3341-8 [9400986.001]
  • [Cites] Clin Infect Dis. 1998 Jan;26(1):132-7 [9455521.001]
  • [Cites] J Virol. 1998 Mar;72(3):2010-21 [9499055.001]
  • [Cites] Adv Virus Res. 1998;50:69-99 [9520997.001]
  • [Cites] Virology. 1998 Apr 10;243(2):492-6 [9568046.001]
  • [Cites] J Neurovirol. 1998 Apr;4(2):242-5 [9584961.001]
  • [Cites] Brain Pathol. 1999 Jan;9(1):33-42 [9989448.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3607-13 [10207084.001]
  • (PMID = 20387126.001).
  • [ISSN] 1557-1904
  • [Journal-full-title] Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
  • [ISO-abbreviation] J Neuroimmune Pharmacol
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / 1R01AI074626-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2914282
  •  go-up   go-down


70. Samaras V, Stamatelli A, Samaras E, Stergiou I, Konstantopoulou P, Varsos V, Judkins AR, Biegel JA, Barbatis C: Atypical teratoid/rhabdoid tumor of the central nervous system in an 18-year-old patient. Clin Neuropathol; 2009 Jan-Feb;28(1):1-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor of the central nervous system in an 18-year-old patient.
  • OBJECTIVE: Atypical teratoid/rhabdoid tumors are aggressive neoplasms of the central nervous system occurring mainly in the early childhood and rarely in adults.
  • We described a case of this tumor in an 18-year-old male patient without previous medical history.
  • MATERIAL AND METHODS: The neoplasm was localized in the right frontotemporal area of the brain and was totally excised.
  • The histological and immunohistochemical features of the neoplasm were assessed, while sequencing analysis as well as interphase fluorescence in situ hybridization (FISH) were performed.
  • INI1 immunostaining demonstrated diffuse loss of nuclear INI1 expression in tumor cells.
  • Taken together, the results were consistent with a diagnosis of atypical teratoid/rhabdoid tumor (ATRT).
  • To our knowledge, this is the eighth case of an ATRT reported in an adult patient having genetic confirmation and the first one in which the tumor is, partly, localized in the right temporal area of the brain.
  • This unusual presentation underlines the necessity of considering this devastating neoplasm in the differential diagnosis of malignant brain tumors of young adults.

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Neuropathol. 2006 Mar-Apr;25(2):81-5 [16550741.001]
  • [Cites] Neuropathology. 2006 Feb;26(1):57-61 [16521480.001]
  • [Cites] J Neurooncol. 2007 Sep;84(2):217-22 [17431546.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):321-30 [18369529.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):49-55 [17377740.001]
  • [Cites] Pathol Int. 1999 Dec;49(12):1114-8 [10632935.001]
  • [Cites] No Shinkei Geka. 2000 Apr;28(4):351-8 [10769834.001]
  • [Cites] Neuroradiology. 2000 May;42(5):363-7 [10872158.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):156-62 [11230702.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):49-56 [11451202.001]
  • [Cites] Pediatr Neurosurg. 2002 Aug;37(2):64-70 [12145514.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):121-6 [12622450.001]
  • [Cites] Neurol India. 2003 Jun;51(2):273-4 [14571026.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] Acta Neurochir (Wien). 2004 Sep;146(9):1033-8; discussion 1038 [15340816.001]
  • [Cites] Urol Radiol. 1985;7(1):42-4 [2984819.001]
  • [Cites] Acta Neuropathol. 1992;83(4):445-8 [1575023.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):81-5 [7679853.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2002-6 [7801128.001]
  • [Cites] Semin Diagn Pathol. 1995 Aug;12(3):233-48 [8545590.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Can J Neurol Sci. 1996 Nov;23(4):257-63 [8951203.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):223-7 [9024522.001]
  • [Cites] Nature. 1998 Jul 9;394(6689):203-6 [9671307.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):74-9 [9892189.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):247 [10477033.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):23-8 [15779233.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):77-84 [15803379.001]
  • [Cites] J Neurooncol. 2005 Sep;74(3):311-9 [16132523.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):907-15 [16221059.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):309-13 [16195799.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1038-43 [16406394.001]
  • (PMID = 19216214.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA046274-17A2; United States / NCI NIH HHS / CA / R01 CA046274; United States / NCI NIH HHS / CA / CA 46274; United States / NCI NIH HHS / CA / R01 CA046274-17A2
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  • [Other-IDs] NLM/ NIHMS113796; NLM/ PMC2712356
  •  go-up   go-down


71. Kalaghchi B, Kazemian A, Hassanloo J, Zendehdel K: Granulocyte colony stimulating factor for prevention of craniospinal radiation treatment interruption among central nervous system tumor patients. Asian Pac J Cancer Prev; 2010;11(6):1499-502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocyte colony stimulating factor for prevention of craniospinal radiation treatment interruption among central nervous system tumor patients.
  • OBJECTIVES: In this pilot randomized clinical trial the preventive effects of weekly granulocyte colony stimulating factor (GCSF) injection for patients with central nervous system (CNS) tumors receiving craniospinal irradiation were assessed with regard to risk of treatment interruption.
  • METHODS: We randomized 40 CNS cancer patients into two groups (20 patients each), the first receiving GCSF prevention therapy before weekly craniospinal radiotherapy and the control group without this prophylaxis.
  • CONCLUSION: Weekly GSCF injections among CNS tumor patients receiving craniospinal therapy may decrease treatment interruption.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Cranial Irradiation. Granulocyte Colony-Stimulating Factor / therapeutic use. Spine / drug effects. Spine / radiation effects
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Pilot Projects. Prospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21338187.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Thailand
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


72. Zhou J, Li NY, Zhou XJ, Zhou HB, Wu B, Jiang SJ, Ma HH, Zhang RS: [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system]. Zhonghua Bing Li Xue Za Zhi; 2010 Mar;39(3):145-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system].
  • OBJECTIVE: To study clinicopathologic features, diagnosis, treatment and prognosis of von Hippel-Lindau (VHL) syndrome-related and sporadic hemangioblastomas of the central nervous system (CNS-HB).
  • METHODS: Histopathological, ultrastructural, immunohistochemical (EnVision method) and clinical features of 21 VHL syndrome and 63 sporadic CNS-HB cases were studied with correlation of the available follow-up information.
  • RESULTS: Twenty-one VHL patients accompanied with a total of 87 CNS-HBs, including one patient of developing 12 HBs within 13 years.
  • There were 10 patients presenting other lesions related to VHL, including 6 retinal HBs, 4 pancreatic tumors (endocrine tumor and microcystic cystadenoma), 1 clear renal cell carcinoma, 4 renal cysts and 1 endolymphatic sac tumor.
  • One patient developed 5 different tumors related to VHL within a period of 4 years.
  • In the 63 cases of sporadic CNS-HB (34 male and 29 female), the mean age was 43.0 years.
  • Histologically, the tumors showed large and vacuolated stromal cells.
  • Some tumors showed atypical nuclei.
  • Tumor cells of HB stained positive for vimentin, EGFR, Inhibin alpha and D2-40, but negative for CD34 and CD68.
  • The syndrome is characterized by development of various benign and malignant tumors.
  • The most common tumor is CNS-HB, which occurs predominantly in the cerebellum.
  • Patients with VHL syndrome tend to present at a younger age than patients with sporadic CNS-HBs, and VHL related HB occurs more predominantly in the brain stem and spinal cord.
  • Prognosis of CNS-HB patients is not correlated with the nuclear atypicality, expression for Ki-67 and involvement of the brain tissue.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Hemangioblastoma / pathology. von Hippel-Lindau Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Child. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / metabolism. Humans. Inhibins / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Receptor, Epidermal Growth Factor / metabolism. Retinal Neoplasms / metabolism. Retinal Neoplasms / pathology. Retinal Neoplasms / surgery. Survival Analysis. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Von Hippel-Lindau syndrome.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450758.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Vimentin; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


73. Morikawa Y, Hisaoka T, Kitamura T, Senba E: TROY, a novel member of the tumor necrosis factor receptor superfamily in the central nervous system. Ann N Y Acad Sci; 2008 Apr;1126:A1-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TROY, a novel member of the tumor necrosis factor receptor superfamily in the central nervous system.
  • Using a signal sequence trap method, we isolated TROY, a novel member of the tumor necrosis factor receptor superfamily (TNFRSF), from a mouse brain cDNA library.
  • In the developing central nervous system, TROY mRNA was strongly expressed in the ventricular and subventricular zones, which contain neuronal and glial precursors during mouse embryogenesis that are both region-specific and stagedependent.
  • Next, we focused on the detailed cellular characterization of TROY-expressing cells in the developing olfactory system.TROYmRNAwas first detected in the olfactory nerve layer (ONL) of the olfactory bulb at E13.5 and was expressed most intensely in the inner ONL (ONL-i) during late embryogenesis.
  • Thus, TROY was expressed in some specific subsets of glial cells in the olfactory bulb, including OECs, and may play some roles in the developing and adult olfactory system.
  • [MeSH-major] Central Nervous System / metabolism. Olfactory Bulb / metabolism. Receptors, Tumor Necrosis Factor / genetics

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18584774.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF19 protein, human; 0 / Tnfrsf19 protein, mouse
  •  go-up   go-down


74. Villano JL, Virk IY, Ramirez V, Propp JM, Engelhard HH, McCarthy BJ: Descriptive epidemiology of central nervous system germ cell tumors: nonpineal analysis. Neuro Oncol; 2010 Mar;12(3):257-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive epidemiology of central nervous system germ cell tumors: nonpineal analysis.
  • Central nervous system (CNS) germ cell tumors (GCT) have not been epidemiologically well described.
  • Our study describes 2 population-based series of nonpineal CNS GCT.
  • Data on all primary (malignant and nonmalignant) CNS (ICD-O-3 sites: C70.0-C72.9, C75.1-C75.3) GCT diagnosed between 2000 and 2004 from the Central Brain Tumor Registry of the United States (CBTRUS) and on all malignant GCT diagnosed between 1992 and 2005 from the Surveillance, Epidemiology, and End Results (SEER) were analyzed.
  • For children and young adults, most tumors were malignant (86.8% and 89.0%, respectively), whereas for adults, more than half were nonmalignant (56.8%).
  • In SEER, the frequency of malignant GCT in the CNS (2.5%) was greater than that in the mediastinum (2.1%).
  • Of 408 malignant CNS GCT, 216 (52.9%) were nonpineal.
  • Overall relative survival for nonpineal CNS malignant GCT was 85.3% at 2 years, 77.3% at 5 years, and 67.6% at 10 years.
  • Nonpineal CNS GCT show no significant gender preference, yet have outcomes similar to pineal GCT.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Neoplasms, Germ Cell and Embryonal / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Registries. SEER Program. United States / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2585-92 [10561326.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):121-30 [18287340.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1171-6 [10725628.001]
  • [Cites] Oncologist. 2000;5(4):312-20 [10964999.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):815-21 [11005262.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7268-76 [11585765.001]
  • [Cites] Int J Clin Oncol. 2001 Aug;6(4):183-91 [11706556.001]
  • [Cites] Brain Tumor Pathol. 2001;18(2):115-22 [11908867.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):487-500 [12354131.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):846-53 [14990640.001]
  • [Cites] Pediatr Blood Cancer. 2004 Aug;43(2):126-33 [15236278.001]
  • [Cites] Am J Clin Pathol. 1976 Apr;65(4):450-4 [178171.001]
  • [Cites] J Neurosurg. 1985 Aug;63(2):155-67 [2991485.001]
  • [Cites] Int J Androl. 1987 Feb;10(1):43-9 [3034798.001]
  • [Cites] J Neurosurg. 1987 Jul;67(1):65-70 [2439668.001]
  • [Cites] AJNR Am J Neuroradiol. 1989 Sep-Oct;10(5):1039-44 [2476011.001]
  • [Cites] Pediatr Pathol. 1990;10(1-2):231-41 [2156245.001]
  • [Cites] Chest. 1991 Feb;99(2):472-9 [1846573.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):545-51 [1848284.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Dec;5(6):1189-209 [1663939.001]
  • [Cites] Radiat Med. 1992 Mar-Apr;10(2):55-61 [1320768.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):229-45 [8270446.001]
  • [Cites] Neuropediatrics. 1994 Feb;25(1):26-32 [8208347.001]
  • [Cites] Med Pediatr Oncol. 1995 Jun;24(6):368-72 [7536294.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] J Neurooncol. 1997 Mar;32(1):71-80 [9049865.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):681-90 [9264351.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1792-7 [9351549.001]
  • [Cites] Childs Nerv Syst. 1999 Mar;15(2-3):119-26; discussion 127 [10230668.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):133-7 [10413166.001]
  • [Cites] Bull N Y Acad Med. 1950 Jul;26(7):440-60 [15426876.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] J Neurosurg. 2005 Dec;103(6 Suppl):524-30 [16383251.001]
  • [Cites] Obstet Gynecol. 2006 May;107(5):1075-85 [16648414.001]
  • [Cites] Urology. 2006 Aug;68(2):402-5; discussion 405 [16904461.001]
  • [Cites] Neurology. 2007 May 15;68(20):1668-73 [17502547.001]
  • [Cites] Childs Nerv Syst. 2008 Jan;24(1):71-8 [17906866.001]
  • [Cites] J Neurooncol. 1999 Aug;44(1):71-6 [10582672.001]
  • (PMID = 20167813.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2940596
  •  go-up   go-down


75. Bauchet L, Rigau V, Mathieu-Daudé H, Fabbro-Peray P, Palenzuela G, Figarella-Branger D, Moritz J, Puget S, Bauchet F, Pallusseau L, Duffau H, Coubes P, Trétarre B, Labrousse F, Dhellemmes P, Société Française de Neurochirurgie Pédiatrique, Société Française de Neurochirurgie, Société Française de Neuropathologie, Association des Neuro-Oncologues d'Expression Française: Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol; 2009 Mar;92(1):87-98

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical epidemiology for childhood primary central nervous system tumors.
  • This work was conducted by the French Brain Tumor Data Bank (FBTDB) and aims to prospectively record all primary central nervous system tumors (PCNST), in France, for which histological diagnosis is available.
  • The Tumor Registry from Herault was authorized to compile the data files with personal identifiers.
  • About 1,017 cases (533 boys and 484 girls) of newly diagnosed childhood PCNST have been recorded (gliomas: 52%, all other neuroepithelial tumors: 31%, craniopharyngioma: 5%, germ cell tumors, meningioma and neurinoma: approximately 3% each, all histological subtypes have been detailed).
  • Tumor resections were performed in 83.3%, and biopsies in 16.7%.
  • The distributions by histology, cryopreservation of the samples, age, sex, tumor site and surgery have been detailed.
  • The long term goals of the FBTDB are to create a national registry and a network to perform epidemiological studies, to implement clinical and basic research protocols, and to evaluate and harmonize the healthcare of children and adult patients affected by PCNST.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Registries
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. France / epidemiology. Humans. Infant. Infant, Newborn. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020806.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Investigator] Aghakhani N; Ali Benali M; Alliez B; Amat D; Amlashi A; Arbez-Gindre F; Arbion F; Assaker R; Aubriot Lorton MH; Auque J; Autricque A; Auvigne I; Averous G; Baldet P; Bataille B; Bazin A; Beaurain J; Benezech J; Bergemer Fouquet A; Besson G; Beuvon F; Billotet C; Blond S; Boetto S; Boissonnet H; Bonyhay G; Bouillot P; Bourgeois P; Bouvier C; Brassier G; Broche C; Brunon J; Cabal P; Cahn V; Caire F; Calvet P; Cazals-Hatem D; Chapon F; Chazal J; Civit T; Colnat S; Colombat M; Comoy J; Couvelard A; Czorny A; Dam Hieu P; Daumas-Duport C; Dautheribes M; David P; Debono B; Delage Corre M; Delhaye M; Delisle MB; Delsol G; Derlon JM; Desenclos C; Desplat A; Devaux B; Di Rocco F; Diaz A; Diebold MD; Dorfmuller G; Dran G; Dufour T; Dumas B; Dumollard JM; Durand L; Duthel R; Eimer S; El Fertit H; Emery E; Espagno C; Esposito P; Etchandy MP; Eyremandi RP; Faillot T; Felix S; Fernandez C; Fesselet J; Fontaine D; Fournier D; François P; Froelich S; Fuentes JM; Fuentes S; Gadan R; Gaspard C; Gay G; Gigaud M; Gil Robles S; Godard J; Gontier MF; Goujon JM; Gray F; Grignon Y; Grisoli F; Guarnieri J; Guyotat J; Hallacq P; Hamlat A; Hayek G; Heitzmann A; Hennequin V; Huot JC; Irthum B; Jacquet G; Jan M; Jaubert F; Jouanneau E; Jouvet A; Justrabo E; Kalamarides M; Kehrli P; Kemeny JL; Keravel Y; Kerdraon R; Khalil T; Khouri K; Khouri S; Klein O; Kujas M; Lacroix C; Lagarrigue J; Langlois O; Lapierre F; Laquerriere A; Laurent MC; Le Gall F; Le Guerinel C; Le Houcq M; Lechapt E; Legars D; Lemaire JJ; Lena G; Lepeintre JF; Leriche B; Lescure JP; Levillain P; Liguoro D; Lioret E; Listrat A; Loiseau H; Lonjon M; Lopes M; Lot G; Louis E; Maheut-Lourmière J; Maillard A; Maitre F; Maitrot D; Majek-Zakine E; Mandonnet E; Manzo N; Marchal JC; Marie B; Maurage CA; Menei P; Mercier P; Mergey E; Metellus P; Michalak S; Michiels JF; Milinkevitch S; Mineo JF; Miquel C; Mireau E; Mohr M; Mokhtari K; Morandi X; Morar S; Moreau JJ; Moreno S; Mourier KL; Mottolese C; Nataf F; Neuville A; Nogues L; Noudel R; Nuti C; Page P; Paquis P; Parent M; Parker F; Pasqualini F; Patey M; Pelissou-Guyotat I; Peoc'h M; Peragut JC; Peruzzi P; Pierre-Kahn A; Pinelli C; Polivka M; Pommepuy I; Ponnelle T; Porhiel V; Proust F; Quintin-Roue I; Ragragui O; Rasendrarijao D; Raynaud P; Redondo A; Renjard L; Reyns N; Richard S; Richaud J; Riem T; Riffaud L; Ringenbach F; Robert G; Roche PH; Rodriguez MA; Roujeau T; Rousseaux P; Rousselet MC; Roux FE; Roux FX; Ruchoux MM; Sabatier J; Sabatier P; Saïkali S; Saint Andre JP; Saint Pierre G; Saint-Rose C; San Galli F; Sautreaux JL; Sawan B; Scavarda D; Segnarbieux F; Seigneuret E; Sindou M; Sorbara R; Sorin A; Stilhart B; Straub P; Taha S; Ternier JP; Tortel MC; Toussaint P; Touzet G; Tremoulet M; Trouillas J; Tubiana A; Uro-Coste E; Vandenbos F; Varlet P; Velut S; Vidal J; Viennet G; Vignaud JM; Vignes JR; Vinchon M; Vital A; Wager M; Weinbreck N; Zerah M
  •  go-up   go-down


76. Buell JF, Gross TG, Hanaway MJ, Trofe J, Roy-Chaudhury P, First MR, Woodle ES: Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc; 2005 Mar;37(2):954-5
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttransplant lymphoproliferative disorder: significance of central nervous system involvement.
  • BACKGROUND: Few data exist regarding central nervous system (CNS) involvement in patients with posttransplant lymphoproliferative disorder (PTLD).
  • The purpose of this study was to review the Israel Penn International Transplant Tumor Registry (IPITTR) experience with CNS involvement by PTLD.
  • METHODS: Nine hundred ten PTLD cases from the United States were reported to the IPITTR and reviewed for CNS involvement.
  • RESULTS: One hundred thirty-six transplant recipients with PTLD (15%) had CNS involvement.
  • The highest incidence of CNS involvement occurred in pancreas (3 of 11; 27%) and kidney transplant recipients (76 of 429; 18%).
  • For both children and adults, isolated CNS disease was associated with better survival when compared with multiple-site involvement (children: 29% vs 0%; adults: 12% vs 6%; P < .05).
  • Three-year survival in PTLD patients with CNS involvement was 9.4% and without CNS involvement was 49.4% (P < .01).
  • CONCLUSIONS: CNS involvement in transplant recipients with PTLD carries an ominous prognosis; however, isolated CNS involvement has a better prognosis than CNS plus extracranial involvement.
  • Radiation therapy alone provides the best results, but this may be a reflection of isolated CNS disease.
  • [MeSH-major] Central Nervous System / immunology. Kidney Transplantation / immunology. Lymphoproliferative Disorders / epidemiology. Postoperative Complications / immunology
  • [MeSH-minor] Adult. Child. Humans. Registries. Retrospective Studies. United States

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848587.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


77. Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, Mavroudis D, Georgoulias V: Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. Breast Cancer Res; 2006;8(4):R36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.
  • INTRODUCTION: To evaluate the incidence of central nervous system (CNS) involvement in patients with breast cancer treated with a taxane-based chemotherapy regimen and to determine predictive factors for CNS relapse.
  • METHODS: The medical files of patients with early breast cancer (n = 253) or advanced stage breast cancer (n = 239) as well of those with other solid tumors (n = 336) treated with or without a taxane-based chemotherapy regimen during a 42-month period were reviewed.
  • HER2/neu overexpression was identified by immunohistochemistry, whereas cytokeratin 19 (CK-19) mRNA-positive circulating tumor cells (CTCs) in the peripheral blood were identified by real-time PCR.
  • RESULTS: The incidence of CNS relapse was similar in patients suffering from breast cancer or other solid tumors (10.4% and 11.4%, respectively; P = 0.517).
  • The incidence of CNS relapse was significantly higher in breast cancer patients with advanced disease (P = 0.041), visceral disease and bone disease (P = 0.036), in those who were treated with a taxane-containing regimen (P = 0.024), in those with HER2/neu-overexpressing tumors (P = 0.022) and, finally, in those with detectable CK-19 mRNA-positive CTCs (P = 0.008).
  • Multivariate analysis revealed that the stage of disease (odds ratio, 0.23; 95% confidence interval, 0.007-0.23; P = 0.0001), the HER2/neu status (odds ratio, 29.4; 95% confidence interval, 7.51-101.21; P = 0.0001) and the presence of CK-19 mRNA-positive CTCs (odds ratio, 8.31; 95% confidence interval, 3.97-12.84; P = 0.001) were independent predictive factors for CNS relapse.
  • CONCLUSION: CNS relapses are common among breast cancer patients treated with a taxane-based chemotherapy regimen, patients with HER2/neu-positive tumor and patients with CK-19 mRNA-positive CTCs.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / physiopathology. Central Nervous System Neoplasms / physiopathology. Neoplastic Cells, Circulating
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Humans. Keratin-19. Middle Aged. Neoplasm Staging. Predictive Value of Tests. RNA, Messenger. Receptor, ErbB-2 / biosynthesis. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Feb 24;342(8):525-33 [10684910.001]
  • [Cites] Ann Oncol. 2005 Nov;16(11):1772-7 [16150805.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):353-6 [11332148.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):53-7 [11905606.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3404-12 [12177100.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):4130-3 [12351617.001]
  • [Cites] J Clin Invest. 2002 Nov;110(9):1309-18 [12417570.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):2972-7 [12784331.001]
  • [Cites] Ann Oncol. 2003 Jun;14(6):849-55 [12796021.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1072-7 [12853349.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5145-51 [14613993.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):639-43 [15266327.001]
  • [Cites] Adv Neurol. 1978;19:579-92 [570349.001]
  • [Cites] Cancer. 1979 Nov;44(5):1913-8 [498057.001]
  • [Cites] Cancer. 1981 Feb 1;47(3):554-60 [7226005.001]
  • [Cites] Eur J Cancer. 1981 Apr;17(4):449-53 [7308254.001]
  • [Cites] Cancer. 1983 Dec 15;52(12):2349-54 [6640506.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34(6):465-71 [7923556.001]
  • [Cites] Ann Oncol. 1994 Dec;5(10):951-3 [7696168.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):232-6 [8625097.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1113-24 [10393719.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1640-4 [15520065.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8185-94 [15623593.001]
  • [Cites] QJM. 2000 Sep;93(9):611-5 [10984556.001]
  • (PMID = 16846533.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Keratin-19; 0 / RNA, Messenger; 0 / Taxoids; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC1779464
  •  go-up   go-down


78. Mekni A, Kourda J, Hammouda KB, Tangour M, Kchir N, Zitouna M, Haouet S: Solitary fibrous tumour of the central nervous system: pathological study of eight cases and review of the literature. Pathology; 2009;41(7):649-54
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumour of the central nervous system: pathological study of eight cases and review of the literature.
  • AIMS: Solitary fibrous tumours (SFT) of the central nervous system are rare neoplasms that usually present as dura-based masses and clinically resemble meningiomas.
  • [MeSH-major] Brain Neoplasms / pathology. Solitary Fibrous Tumors / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease-Free Survival. Dura Mater / pathology. Female. Hemangiopericytoma / diagnosis. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Meningioma / diagnosis. Middle Aged. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19672786.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


79. Mekni A, Kourda J, Chelly I, Ferchichi L, Bellil K, Hammouda KB, Kchir N, Zitouna M, Khaldi M, Haouet S: Hemangiopericytoma in the central nervous system. A study of eight cases. Neurochirurgie; 2008 Feb;54(1):15-20
Genetic Alliance. consumer health - Hemangiopericytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangiopericytoma in the central nervous system. A study of eight cases.
  • Most hemangiopericytomas (HPC) are located in the musculoskeletal system and the skin, while the location in the central nervous system (CNS) is rare.
  • The latter represents 2 to 4% in large series of meningeal tumors, thus accounting for less than 1% of all CNS tumors.
  • In the central nervous system, tumors with a hemangiopericytomatous histolopathological pattern can be either hemangiopericytomas or solitary fibrous tumors.
  • CNS-HPCs have a relentless tendency for local recurrence and metastases outside the CNS.
  • Metastasis can also appear many years after adequate treatment of the primary tumor.
  • We present a pathological study of eight patients with CNS-HPC and compare our results with corresponding published data.
  • The CNS-HPC group consisted of three males and five females with a mean age of 36.75 years.
  • The tumors were supratentorial in four cases, infratentorial in two cases, tentorial in one case and located in the spinal cord in the last one.
  • Histologically, CNS-HPCs were similar to their soft tissue counterparts.
  • Our study presents the pathological features of CNS-HPC as a distinct entity from both meningioma and solitary fibrous tumors.
  • [MeSH-major] Central Nervous System Neoplasms / surgery. Hemangiopericytoma / surgery
  • [MeSH-minor] Adult. Antigens, CD34 / metabolism. Female. Humans. Immunohistochemistry. Infratentorial Neoplasms / pathology. Infratentorial Neoplasms / surgery. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neuroglia / pathology. Neurosurgical Procedures. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / surgery. Supratentorial Neoplasms / pathology. Supratentorial Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18308345.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


80. Sundaram C, Uppin SG, Uppin MS, Rekha JS, Panigrahi MK, Purohit AK, Rammurti S: A clinicopathological and immunohistochemical study of central nervous system hemangiopericytomas. J Clin Neurosci; 2010 Apr;17(4):469-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological and immunohistochemical study of central nervous system hemangiopericytomas.
  • Hemangiopericytomas (HPC) of the central nervous system (CNS) are uncommon dural-based tumors that mimic meningiomas clinically and radiologically.
  • Because there are few reports about these tumors from India, we aimed to study the clinico-pathological and immunohistochemical features of CNS HPC.
  • During 2000 to 2008 all 23 patients diagnosed with HPC of CNS at our Institution were reviewed in the study (11 males and 12 females, mean age of 46 years).
  • There were 14 patients with grade II and nine with grade III tumors.
  • Immunohistochemistry with antibodies to epithelial membrane antigen (EMA), vimentin, S-100, CD34 and Ki-67 was done on routinely processed, paraffin-embedded sections of 20 tumors.
  • The mean Ki-67 labeling index was 4.25% in grade II tumors and 7.8% in grade III tumors.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Hemangiopericytoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Meningeal Neoplasms / pathology. Meningioma / pathology. Middle Aged. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20167500.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


81. Yokosuka K, Ishii R, Suzuki Y, Hirano K, Ishii N, Sekihara Y, Hamazaki S, Nishimura H: Extraneural metastasis of high grade glioma without simultaneous central nervous system recurrence: case report. Neurol Med Chir (Tokyo); 2007 Jun;47(6):273-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraneural metastasis of high grade glioma without simultaneous central nervous system recurrence: case report.
  • He had undergone a shunt operation and three tumor removals during a 6-year period.
  • Autopsy revealed tumor masses in the peritoneum, pleura, bone marrow, lymph nodes, and other organs, but no recurrent tumor of the primary lesion or metastases to other areas in the central nervous system.
  • Systemic metastases from primary intracranial tumors are rare, but are likely to become more frequent as the prognosis of patients with brain tumors improves and the duration of survival lengthens.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Brain Neoplasms / pathology. Glioma / secondary. Neoplasm Metastasis / physiopathology. Peritoneal Neoplasms / secondary. Pleural Neoplasms / secondary
  • [MeSH-minor] Adult. Central Nervous System / pathology. Drug Therapy. Fatal Outcome. Humans. Lymph Nodes / pathology. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / physiopathology. Pulvinar / pathology. Pulvinar / physiopathology. Radiotherapy. Survival Rate

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587781.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


82. Robertus JL, Harms G, Blokzijl T, Booman M, de Jong D, van Imhoff G, Rosati S, Schuuring E, Kluin P, van den Berg A: Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol; 2009 Apr;22(4):547-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma.
  • Apart from 19 nodal cases without extranodal dissemination (stages I and II), we selected two groups with unambiguous stages I and II extranodal presentation; 9 cases of primary central nervous system, 11 cases of primary testicular and 11 cases of other primary extranodal diffuse large B-cell lymphomas.
  • In situ hybridization for the most differentially expressed miRNAs was performed to show miRNA expression in tumor cells, but not in background cells.
  • MiR-17-5p showed a significant higher expression level in the central nervous system compared with testicular and nodal diffuse large B-cell lymphomas (P<0.05).
  • MiR-127 levels were significantly higher in testicular than in central nervous system and in nodal diffuse large B-cell lymphomas (P<0.05).
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. MicroRNAs / biosynthesis. Testicular Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Germinal Center / pathology. Humans. In Situ Hybridization. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287466.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN17 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


83. Goodwin TL, Sainani K, Fisher PG: Incidence patterns of central nervous system germ cell tumors: a SEER Study. J Pediatr Hematol Oncol; 2009 Aug;31(8):541-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence patterns of central nervous system germ cell tumors: a SEER Study.
  • BACKGROUND: Incidence patterns of central nervous system (CNS) germ cell tumors (GCTs) have been reported, but the influence of underlying host risk factors has not been rigorously explored.
  • We aimed to determine in a large, population-based cancer registry how age, sex, and race, influence the occurrence of CNS GCTs in the pediatric population.
  • The cases were limited to only those with the International Classification of Childhood Cancer Xa: intracranial and intraspinal germ-cell tumors.
  • Incidence rates (per 10,000) for each sex and race were plotted for single-age groups, and then stratified by tumor location and pathology subtype.
  • Males had significantly higher rates of CNS GCTs than females.
  • Tumor location differed strikingly by sex (P<0.0001) with pineal location more common in males (61.0% vs. 15.5%).
  • Asian race was associated with a higher rate of CNS GCTs than other races.
  • CONCLUSIONS: Males have higher incidence of CNS GCTs, primarily germinomas, than females, starting in the second decade.
  • Pineal location is strongly associated with male sex, with pineal germinomas representing over half of all CNS GCTs in males.
  • These findings suggest a robust but poorly understood influence of sex, either genetic or hormonal, and race on the occurrence of CNS GCTs.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Neoplasms, Germ Cell and Embryonal / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Female. Humans. Incidence. Male. Middle Aged. Registries. Retrospective Studies. Sex Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19636276.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Arai M, Sasaki A, Saito N, Nakazato Y: Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system. Pathol Int; 2005 Mar;55(3):122-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system.
  • The purpose of the present paper was to examine the level of apoptosis and the relationships among apoptosis, apoptosis-associated proteins, and proliferating potential in lymphoma tissues to clarify the characteristics of apoptosis in diffuse large B-cell lymphomas (DLBCL) of the central nervous system (CNS).
  • The formalin-fixed, paraffin-embedded tissues of CNS and non-CNS DLBCL (20 cases each) were studied by terminal deoxynucleotidyl transferase-mediated dUTP-nick end labeling (TUNEL) and immunohistochemistry, using antibodies against single-stranded DNA (ssDNA), cleaved caspase-3, bcl-2, bax, p53, Fas and Ki-67.
  • High expression (grade + + or + + +) of cleaved caspase-3 was found more frequently in CNS DLBCL (11 cases, 55%) than non-CNS DLBCL (three cases, 15%; P = 0.009).
  • Bax-positivity of lymphoma cells was increased in six cases of CNS DLBCL, which also showed high positivity of cleaved caspase-3.
  • The present study indicates that the number of apoptotic cells and expression level of cleaved caspase-3 were significantly higher in CNS DLBCL than non-CNS DLBCL, and that the correlation of bax and cleaved caspase-3 expression was often present in CNS DLBCL.
  • [MeSH-major] Apoptosis. Brain Neoplasms / enzymology. Caspases / metabolism. Lymphoma, B-Cell / enzymology. Lymphoma, Large B-Cell, Diffuse / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Caspase 3. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunoenzyme Techniques. In Situ Nick-End Labeling. Ki-67 Antigen / metabolism. Male. Middle Aged

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743320.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


85. Ponzoni M, Kwee I, Mazzucchelli L, Ferreri AJ, Zucca E, Doglioni C, Cavalli F, Bertoni F: A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals. Pathobiology; 2007;74(4):264-9
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals.
  • Primary central nervous system lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin's lymphoma with continuously increasing incidence in both immunosuppressed and immunocompetent individuals.
  • PCNSL is a very aggressive tumor with a poor outcome, and its clinical outcome is much worse than for nodal lymphomas.
  • [MeSH-major] Brain Neoplasms / immunology. Brain Neoplasms / pathology. Immunocompetence. Information Dissemination / methods. Lymphoma / immunology. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Humans. Internet. Middle Aged. Software. Tissue Banks

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17709970.001).
  • [ISSN] 1423-0291
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


86. Behdad A, Perry A: Central nervous system primitive neuroectodermal tumors: a clinicopathologic and genetic study of 33 cases. Brain Pathol; 2010 Mar;20(2):441-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system primitive neuroectodermal tumors: a clinicopathologic and genetic study of 33 cases.
  • Central nervous system (CNS) primitive neuroectodermal tumors (PNETs) include supratentorial, brain stem, and spinal cord tumors with medulloblastoma-like histopathology.
  • After re-diagnosis of three infantile cases as atypical teratoid/rhabdoid tumor (AT/RT), 33 remaining CNS PNETs were retrieved for clinicopathologic and fluorescence in situ hybridization studies.
  • We conclude that in CNS PNET: (i) routine application of INI1 immunohistochemistry helps rule out AT/RT, particularly in infants;.
  • (iii) involvement of CNS parenchyma by Ewing sarcoma/peripheral PNET is rare enough that EWS gene testing is not necessary unless significant dural involvement is present; and (iv) both anaplastic/large cell features and polysomies of 2 and 8 are associated with more aggressive clinical behavior.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Neuroectodermal Tumors, Primitive / genetics. Neuroectodermal Tumors, Primitive / pathology. Spinal Cord Neoplasms / genetics. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aneuploidy. Child. Child, Preschool. Chromosomes, Human, Pair 2. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 8. Female. Humans. Infant. Male. Middle Aged. Nuclear Proteins / genetics. Oncogene Proteins / genetics. RNA-Binding Protein EWS / genetics. Rhabdoid Tumor / diagnosis. Rhabdoid Tumor / genetics. Rhabdoid Tumor / pathology. Teratoma / diagnosis. Teratoma / genetics. Teratoma / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19725831.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / RNA-Binding Protein EWS
  •  go-up   go-down


87. Schneider DT, Zahn S, Sievers S, Alemazkour K, Reifenberger G, Wiestler OD, Calaminus G, Göbel U, Perlman EJ: Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization. Mod Pathol; 2006 Jun;19(6):864-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization.
  • The limited information available to date regarding the genetic alterations in germ cell tumors of the central nervous system has raised concerns about their biologic relationship to other germ cell tumor entities.
  • We investigated fresh-frozen or archival tumor samples from 19 patients with central nervous system germ cell tumors (CNS-GCTs), including seven germinomas, eight malignant nongerminomatous germ cell tumors and four teratomas, using chromosomal comparative genomic hybridization to determine recurrent chromosomal imbalances.
  • All 15 malignant CNS-GCTs and two of four teratomas showed multiple chromosomal imbalances.
  • Chromosomal gains (median: 4 gains/tumor, range: 0-9 gains/tumor) were observed more frequently than losses (median: 1.6 losses/tumor, range: 0-6 losses/tumor).
  • Gain of 12p, which is considered characteristic for germ cell tumors of the adult testis, was detected in 11 of 19 tumors and 10 of 15 malignant CNS-GCTs.
  • In one tumor, gain of 12p was confined to an amplicon at 12p12, corresponding to the commonly amplified region on 12p.
  • Notably, we observed no difference in the genetic profiles of germinomatous and nongerminomatous CNS-GCTs; however, the average number of imbalances was higher in the latter group.
  • A meta-analysis comparing 116 malignant gonadal and extragonadal germ cell tumors revealed that the genomic alterations in CNS-GCTs are virtually indistinguishable from those found in their gonadal or other extragonadal counterparts of the corresponding age group.
  • These data strongly argue in favor of common pathogenetic mechanisms in gonadal and extragonadal germ cell tumors.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Genetic Testing / methods. Neoplasms, Germ Cell and Embryonal / genetics. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. DNA, Neoplasm / analysis. Female. Humans. Infant, Newborn. Male. Meta-Analysis as Topic

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607373.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


88. Agrawal M, Uppin MS, Patibandla MR, Bhattacharjee S, Panigrahi MK, Saradhi V, Rani JY, Purohit AK, Challa S: Teratomas in central nervous system: a clinico-morphological study with review of literature. Neurol India; 2010 Nov-Dec;58(6):841-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Teratomas in central nervous system: a clinico-morphological study with review of literature.
  • AIMS: To study the demographic, clinico-morphological and follow-up data of central nervous system (CNS) teratomas.
  • MATERIALS AND METHODS: Cases diagnosed as mature or immature teratomas in the CNS over a 20-year period were included in the study.
  • RESULTS: A total of 14 tumors were diagnosed as teratomas.
  • Of these, 11 were mature cystic teratomas; and 1 case each, of teratoma with malignant transformation, terato-carcinoma and mixed germ cell tumor (immature teratoma with germinoma).
  • Radiologically, contrast enhancement with predominantly solid component was suggestive of malignancy or an aggressive tumor.
  • Excision was curative or provided symptomatic relief in most cases; terato-carcinoma and mixed germ cell tumor patients needed adjuvant radiotherapy.
  • CONCLUSION: CNS teratomas are rare.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / surgery. Teratoma / diagnosis. Teratoma / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21150046.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  •  go-up   go-down


89. Preusser M, Woehrer A, Koperek O, Rottenfusser A, Dieckmann K, Gatterbauer B, Roessler K, Slavc I, Jaeger U, Streubel B, Hainfellner JA, Chott A: Primary central nervous system lymphoma: a clinicopathological study of 75 cases. Pathology; 2010;42(6):547-52
Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma: a clinicopathological study of 75 cases.
  • AIMS: Pathological and clinical data in a large series of immunocompetent patients with primary lymphoma of the central nervous system (PCNSL) were analysed.
  • [MeSH-major] Biomarkers, Tumor / analysis. Central Nervous System Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. DNA-Binding Proteins / genetics. Female. Forkhead Transcription Factors / genetics. Gene Expression Profiling. Gene Rearrangement. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Repressor Proteins / genetics. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20854073.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / FOXP1 protein, human; 0 / Forkhead Transcription Factors; 0 / Repressor Proteins
  •  go-up   go-down


90. Sezgin C, Gokmen E, Esassolak M, Ozdemir N, Goker E: Risk factors for central nervous system metastasis in patients with metastatic breast cancer. Med Oncol; 2007;24(2):155-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for central nervous system metastasis in patients with metastatic breast cancer.
  • AIMS: Patients with metastatic breast cancer (MBC) and central nervous system (CNS) involvement have an impaired survival and quality of life.
  • In this study, we investigated the risk factors for CNS metastasis among patients with MBC.
  • METHODS: The risk factors for development of CNS metastasis were analyzed in 154 patients with MBC.
  • RESULTS: Median OS was significantly poorer for patients with CNS metastasis as compared with patients with no CNS metastasis (OS, 23 mo vs 30 mo, respectively;p = 0.03).
  • Ki-67 and p53 overexpressions by IHC, and lung metastasis as the first site of relapse, were associated with a higher risk of developing CNS metastasis in the univariate analysis (p <or= 0.05).
  • The presence of lung metastasis (odds ratio [OR]= 2.82, 95% confidence interval [CI]: 1.13-7.00,p = 0.02) and p53 overexpression (OR = 2.44, 95% CI: 0.99-6.00,p = 0.05) were the two predictive factors associated with occurrence of CNS metastasis in the multivariate analysis.
  • CONCLUSIONS: In this study, the presences of lung metastasis as the first site of relapse and p53 overexpression were predictive for the occurrence of CNS metastasis in patients with MBC.
  • Life expectancy of patients with CNS metastasis is significantly shorter than those without CNS metastasis.
  • [MeSH-major] Breast Neoplasms / pathology. Central Nervous System Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lung Neoplasms / secondary. Middle Aged. Predictive Value of Tests. Prevalence. Prognosis. Registries. Risk Factors. Survival Analysis. Tumor Suppressor Protein p53 / analysis


91. Freeman BB 3rd, Daw NC, Geyer JR, Furman WL, Stewart CF: Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest; 2006 Apr-May;24(3):310-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.
  • EGFR expression has been noted in neuroblastoma and rhabdomyosarcoma cell lines and in tumor specimens from children with Wilms tumor, osteosarcoma, and glioma.
  • Thus, gefitinib, the first marketed EGFR tyrosine kinase inhibitor, was chosen for study in children with refractory solid tumors and central nervous system (CNS) malignancies.
  • This review discusses findings from 3 clinical trials of gefitinib in children with refractory solid tumors and CNS malignancies, focusing on the clinical pharmacology of the compound.
  • Finally, the future for the use of gefitinib in pediatrics is similar to that of other molecularly targeted agents and awaits definition of tumors and patient populations in which it will be most advantageous.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Child. Clinical Trials as Topic. Drug Resistance, Neoplasm. Humans. Receptor, Epidermal Growth Factor / drug effects. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809160.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 7673326042 / irinotecan; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 67
  •  go-up   go-down


92. Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C: [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Orv Hetil; 2009 Oct 18;150(42):1937-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic management of central nervous system lymphomas in a single hematological institute].
  • Primary central nervous system lymphoma is defined as an extranodal lymphoma arising in the central nervous system in the absence of systemic disease.
  • AIMS: In this retrospective survey we analyzed the result of combined treatment (systemic and intrathecal chemotherapy followed by consolidation radiotherapy) in patients with primary or relapsed central nervous system lymphomas diagnosed and treated in our hematological department between 1998-2009.
  • PATIENTS AND METHODS: During this period (mean follow-up of 13.2 months) from 427 patients with newly diagnosed non-Hodgkin's lymphomas, 22 primary central nervous system lymphoma was diagnosed (5.15%, 16 cerebral and 6 spinal cord lymphoma cases).
  • All central nervous system lymphoma specimens taken with neurosurgical resection or stereotaxic biopsies were confirmed histopathologically.
  • In case of partial response, boost irradiation for the tumor bed was also given.
  • CONCLUSION: In primary central nervous system lymphoma, basic treatment HD methotrexate together with intrathecal combination of methotrexate + cytosin-arabinosid + dexamethasone followed by whole-brain irradiation of at least 30 Gy could produce a medium response rate in our study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Cranial Irradiation. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Administration Schedule. Epidural Space. Female. Humans. Hungary / epidemiology. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Positron-Emission Tomography. Prednisone / administration & dosage. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Rituximab. Salvage Therapy / methods. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19812012.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down


93. Liao W, Liu Y, Wang X, Jiang X, Tang B, Fang J, Chen C, Hu Z: Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Acta Radiol; 2009 Mar;50(2):217-25
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
  • BACKGROUND: Preoperative differentiation of primary central nervous system lymphomas (PCNSLs) from other tumors is important for presurgical staging, intraoperative management, and postoperative treatment.
  • Microvessel density (MVD) was evaluated using immunohistochemical staining of surgical specimens with anti-CD34, and MVDs of the two tumor groups were compared by using Student's t test.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Contrast Media. Diagnosis, Differential. Female. Gadolinium DTPA. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096950.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


94. Douglas JG, Rockhill JK, Olson JM, Ellenbogen RG, Geyer JR: Cisplatin-based chemotherapy followed by focal, reduced-dose irradiation for pediatric primary central nervous system germinomas. J Pediatr Hematol Oncol; 2006 Jan;28(1):36-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin-based chemotherapy followed by focal, reduced-dose irradiation for pediatric primary central nervous system germinomas.
  • The objective of this study was to evaluate retrospectively one institution's experience treating pediatric central nervous system (CNS) pure germinomas with platinum-based chemotherapy followed by focal, reduced-dose irradiation.
  • Eight patients were identified with localized, pure CNS germinomas from 1993 to 2004 at the authors' institution.
  • The tumor location was suprasellar in four, the pineal region in three, and the third ventricle in one.
  • Two patients suffered marginal (at field edge) failures and both were salvaged using reinduction platinum-based chemotherapy followed by cranial spinal irradiation and a boost to the primary tumor.
  • These data suggest that a reduction in both volume and dose (30.6-36 Gy) retains the excellent survival rates for patients with localized, pure germinomas of the CNS.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Cisplatin / administration & dosage. Germinoma / drug therapy. Germinoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Pituitary Gland / physiology. Radiation Dosage. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16394891.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


95. Lonser RR, Vortmeyer AO, Butman JA, Glasker S, Finn MA, Ammerman JM, Merrill MJ, Edwards NA, Zhuang Z, Oldfield EH: Edema is a precursor to central nervous system peritumoral cyst formation. Ann Neurol; 2005 Sep;58(3):392-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Edema is a precursor to central nervous system peritumoral cyst formation.
  • Despite the common occurrence and frequent clinical effects of peritumoral cysts in the central nervous system (CNS), the mechanism underlying their development and evolution is not understood.
  • Because they commonly produce peritumoral cysts and because serial magnetic resonance imaging (MRI) is obtained in von Hippel-Lindau disease patients, hemangioblastomas provide an opportunity to examine the pathophysiology of CNS peritumoral cyst formation.
  • Serial MRI was correlated with the clinical findings in 16 von Hippel-Lindau disease patients with 22 CNS hemangioblastomas (11 spinal cord; 11 cerebellar) that were associated with the appearance and evolution of peritumoral cysts.
  • MRI clearly showed peritumoral edema that developed and slowly and progressively evolved into enlarging hemangioblastoma-associated cysts in all tumors (mean follow-up, 130 +/- 38 months; mean +/- standard deviation).
  • CNS peritumoral cyst formation is initiated by increased tumor vascular permeability, increased interstitial pressure in the tumor, and plasma extravasation with convective distribution into the surrounding tissue.
  • When the delivery of plasma from the tumor exceeds the capacity of the surrounding tissue to absorb the extravasated fluid, edema (with its associated increased interstitial pressure) and subsequent cyst formation occur.
  • [MeSH-major] Brain Neoplasms / pathology. Central Nervous System Cysts / pathology. Edema / pathology
  • [MeSH-minor] Adult. Autopsy / methods. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging / methods. Male. Time Factors. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor A / cerebrospinal fluid

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16130092.001).
  • [ISSN] 0364-5134
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


96. Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, Rivera E: Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer; 2007 Dec 15;110(12):2640-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis.
  • BACKGROUND: Breast cancer is the second most common cause of central nervous system (CNS) metastases.
  • Several risk factors for CNS metastases have been reported.
  • The objective of the current study was to describe clinicopathologic characteristics and prognostic factors in breast cancer patients with CNS metastases.
  • METHODS: The authors retrospectively evaluated clinical data from 420 patients who had been diagnosed with breast cancer and CNS metastasis between 1994 and 2004 at the University of Texas M. D.
  • Most patients had invasive ductal histology (91.2%), grade 3 tumors (81.4%) (using the modified Black nuclear grading system), T2 tumor classification (40.1%), and N1 lymph node status (59.7%) diagnosis.
  • CNS metastasis was the site of first recurrence in 53 patients (12%).
  • The median time from breast cancer diagnosis to CNS metastasis was 30.9 months (range, from -5 months to 216.7 months).
  • The median follow-up after a diagnosis of CNS metastasis was 6 months (range, 7-95.9 months).
  • CONCLUSIONS: The current results indicated that the prognosis remains patients with breast cancer metastatic to the CNS.
  • More effective treatment approaches are needed for patients with CNS metastases, even for those with favorable prognostic factors, such as ER-positive tumors or younger age.
  • [MeSH-major] Breast Neoplasms / pathology. Central Nervous System Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Time Factors


97. Raizer JJ, Koutcher JA, Abrey LE, Panageas KS, DeAngelis LM, Lis E, Xu S, Zakian KL: Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neurooncol; 2005 Jan;71(2):173-80
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is a highly aggressive tumor responsive to high-dose methotrexate based regimens.
  • MRSI correlated with tumor response or progression on MRI; in three patients MRSI suggested disease progression prior to changes on MRI.
  • CONCLUSION: MRSI and MRI correlate with tumor response or progression and may allow early detection of disease recurrence.
  • [MeSH-major] Aspartic Acid / analogs & derivatives. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / immunology. Immunocompetence. Lymphoma / diagnosis. Lymphoma / immunology. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Choline / metabolism. Creatine / metabolism. Disease Progression. Dose-Response Relationship, Drug. Female. Humans. Lactic Acid / metabolism. Lipid Metabolism. Magnetic Resonance Imaging. Male. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Protons. Survival Analysis

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690135.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Protons; 30KYC7MIAI / Aspartic Acid; 33X04XA5AT / Lactic Acid; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


98. Jensen AW, Laack NN, Buckner JC, Schomberg PJ, Wetmore CJ, Brown PD: Long-term follow-up of dose-adapted and reduced-field radiotherapy with or without chemotherapy for central nervous system germinoma. Int J Radiat Oncol Biol Phys; 2010 Aug 1;77(5):1449-56
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of dose-adapted and reduced-field radiotherapy with or without chemotherapy for central nervous system germinoma.
  • Treatment was irradiation alone or neoadjuvant platinum-based chemotherapy and local irradiation (initial tumor plus margin) for patients with localized complete response and reduced-dose craniospinal irradiation for others.
  • CONCLUSIONS: The addition of neoadjuvant chemotherapy to local-field radiotherapy reduced central nervous system cancer recurrence when high-risk patients were excluded by thorough pretreatment staging.
  • There was trend toward improved central nervous system tumor control when larger fields (whole brain, whole ventricle, or craniospinal axis) were used.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Germinoma / drug therapy. Germinoma / radiotherapy
  • [MeSH-minor] Adolescent. Analysis of Variance. Chemotherapy, Adjuvant / methods. Cisplatin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Humans. Male. Neoadjuvant Therapy / methods. Neoplasm Recurrence, Local. Radiotherapy Dosage. Remission Induction / methods. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20045266.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


99. Cheng J, Tu P, Shi QL, Zhou HB, Zhou ZY, Zhao YC, Ma HH, Zhou XJ: [Primary diffuse large B-cell lymphoma of central nervous system belongs to activated B-cell-like subgroup: a study of 47 cases]. Zhonghua Bing Li Xue Za Zhi; 2008 Jun;37(6):384-9
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diffuse large B-cell lymphoma of central nervous system belongs to activated B-cell-like subgroup: a study of 47 cases].
  • OBJECTIVE: To investigate the histogenetic origin of primary central nervous system diffuse large B-cell lymphoma (DLBCL) with respect to the stage of B-cell differentiation, and identification of the relevant prognostic markers.
  • RESULTS: CD10, bcl-6, MUM-1 and FOXP1 expression in the tumor cells were 6.4%, 53.2%, 91.5% and 93.6% respectively.
  • CONCLUSIONS: Most primary central nervous system DLBCL are shown belonging to the ABC subgroup, suggesting that primary central nervous system DLBCL is quite similar to a DLBCL subset, which is derived from late GC to early post-GC B cell.
  • The classification and FOXP1 expression do not show prognostic value in primary central nervous system DLBCL.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. B-Lymphocytes / pathology. Biomarkers, Tumor / analysis. Central Nervous System. Female. Humans. Male. Middle Aged. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031717.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


100. Brown M, Schrot R, Bauer K, Dodge J: Incidence of first primary central nervous system tumors in California, 2001-2005: children, adolescents and teens. J Neurooncol; 2009 Sep;94(2):263-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of first primary central nervous system tumors in California, 2001-2005: children, adolescents and teens.
  • This study used data from the California Cancer Registry to comprehensively examine first primary central nervous system tumors (PCNST) by the International Classification of Childhood Cancers (ICCC) diagnostic groups and to compare their incidence by age groups, sex, race/ethnicity, socioeconomic status and tumor behavior.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Glioblastoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. California / epidemiology. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19340399.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCCDPHP CDC HHS / DP / 1U58DP00807-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down






Advertisement